1
|
Blumencranz P, Habibi M, Shivers S, Acs G, Blumencranz LE, Yoder EB, van der Baan B, Menicucci AR, Dauer P, Audeh W, Cox CE. ASO Visual Abstract: The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy. Ann Surg Oncol 2024; 31:393-394. [PMID: 37787953 DOI: 10.1245/s10434-023-14317-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Affiliation(s)
| | | | - Steve Shivers
- Comprehensive Breast Cancer Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
| | - Geza Acs
- Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | | | | | | | | | | | | | - Charles E Cox
- Comprehensive Breast Cancer Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
| |
Collapse
|
2
|
Blumencranz P, Habibi M, Shivers S, Acs G, Blumencranz LE, Yoder EB, van der Baan B, Menicucci AR, Dauer P, Audeh W, Cox CE. The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy. Ann Surg Oncol 2023; 30:8353-8361. [PMID: 37658272 PMCID: PMC10625953 DOI: 10.1245/s10434-023-14027-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Accepted: 07/10/2023] [Indexed: 09/03/2023]
Abstract
BACKGROUND Neoadjuvant chemotherapy (NCT) increases the feasibility of surgical resection by downstaging large primary breast tumors and nodal involvement, which may result in surgical de-escalation and improved outcomes. This subanalysis from the Multi-Institutional Neo-adjuvant Therapy MammaPrint Project I (MINT) trial evaluated the association between MammaPrint and BluePrint with nodal downstaging. PATIENTS AND METHODS The prospective MINT trial (NCT01501487) enrolled 387 patients between 2011 and 2016 aged ≥ 18 years with invasive breast cancer (T2-T4). This subanalysis includes 146 patients with stage II-III, lymph node positive, who received NCT. MammaPrint stratifies tumors as having a Low Risk or High Risk of distant metastasis. Together with MammaPrint, BluePrint genomically (g) categorizes tumors as gLuminal A, gLuminal B, gHER2, or gBasal. RESULTS Overall, 45.2% (n = 66/146) of patients had complete nodal downstaging, of whom 60.6% (n = 40/66) achieved a pathologic complete response. MammaPrint and combined MammaPrint and BluePrint were significantly associated with nodal downstaging (p = 0.007 and p < 0.001, respectively). A greater proportion of patients with MammaPrint High Risk tumors had nodal downstaging compared with Low Risk (p = 0.007). When classified with MammaPrint and BluePrint, more patients with gLuminal B, gHER2, and gBasal tumors had nodal downstaging compared with HR+HER2-, gLuminal A tumors (p = 0.538, p < 0.001, and p = 0.013, respectively). CONCLUSIONS Patients with genomically High Risk tumors, defined by MammaPrint with or without BluePrint, respond better to NCT and have a higher likelihood of nodal downstaging compared with patients with gLuminal A tumors. These genomic signatures can be used to select node-positive patients who are more likely to have nodal downstaging and avoid invasive surgical procedures.
Collapse
Affiliation(s)
| | | | - Steve Shivers
- Comprehensive Breast Cancer Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
| | - Geza Acs
- Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | | | | | | | | | | | | | - Charles E Cox
- Comprehensive Breast Cancer Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
| |
Collapse
|
3
|
Wapnir IL, Hunt KK, Hwang ES, Smith K, Blumencranz P, Carr D, Ferrer J, Cruz HS, Webster A, Shanno J, Pogrebinsky A, Chang M, Smith BL. Abstract OT2-07-01: Feasibility study to evaluate performance of the LUM Imaging System for intraoperative detection of residual tumor in breast cancer patients receiving and not receiving neoadjuvant therapy. Cancer Res 2023. [DOI: 10.1158/1538-7445.sabcs22-ot2-07-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
Abstract
Abstract
Background: Microscopically tumor-free lumpectomy margins are critical for safe breast conserving surgery. With current tools, 15%-25% of lumpectomies have positive margins that require second surgical procedures and increase cost and patient discomfort. Additionally, current lumpectomy margin assessment techniques show poor performance in predicting residual disease at re-excision, with a PPV of 35%. Better detection tools are needed to identify residual cancer during the initial lumpectomy and reduce second operations. LUM015 is a protease-activated fluorescent imaging agent that accumulates in tumor cells and tumor associated macrophages after preoperative intravenous injection. The LUM Imaging System visualizes activated LUM015 in the lumpectomy cavity via a hand-held wide field detector and proprietary tumor detection software. This system has been tested in multiple single-site studies and two prospective multi-site studies enrolling >600 patients, and demonstrated successful detection of residual lumpectomy cavity tumor. Initial studies excluded the approximately 20% of patients receiving neoadjuvant therapy. Patchy tumor cell death with preoperative therapy can leave small, multifocal deposits of tumor invisible on pre-operative imaging and not palpable or visible during surgery. We now evaluate the LUM Imaging System in patients with and without neoadjuvant therapy. Trial Design and Specific Aims: This prospective, multi-center study at 6 US sites tests the LUM Imaging System in lumpectomy surgery after neoadjuvant therapy to evaluate potential impact of treatment-related tissue changes and tumor cell death on tumor detection algorithms. An initial cohort of 10 patients address the objective of algorithm development. A second cohort of 104 patients will further evaluate the feasibility of the LUM Imaging System after neoadjuvant therapy. A third cohort will enroll 208 patients who have not received neoadjuvant therapy. All cohorts are evaluated for safety and for reduction in residual tumor after LUM Imaging System guidance compared to standard of care lumpectomy. After excision of the main lumpectomy specimen, patients are randomized 3:1 to device or control arms. In the device arm, the cavity is imaged and margins with LUM015 signal are excised. Final comprehensive shaved margins are removed in both arms to evaluate extent of residual disease after the use of the LUM Imaging System or after standard lumpectomy. No LUM Imaging is performed in the control arm, however, all patients are injected with LUM015 to evaluate drug safety. Patient reported outcomes assessing re-excision concerns, breast appearance and preferences for treatment type are collected. Eligibility Criteria: This study seeks to enroll women 18 and older with histologically confirmed primary invasive breast cancer (IBC), ductal carcinoma in situ (DCIS) or a combination of IBC/DCIS undergoing a lumpectomy for their breast malignancy who have received any form of neoadjuvant treatment prior to surgery (cohorts 1 and 2) or who have not received any therapy prior to lumpectomy (cohort 3). Patients allergic to polyethylene glycol or intravenous contrast agents are excluded. Use of blue node mapping dyes before imaging with the LUM015 is not allowed per study protocol. Accrual and Study Progress: Cohort 1 has completed enrollment and interim analysis. No new risks specific to the neoadjuvant population were identified. LUM015 fluorescent signals measured in neoadjuvant patients were within the expected range, and no changes to the tumor detection algorithm were required. Cohorts 2 and 3 have enrolled a total of 38 patients. This trial is registered as NCT04440982. The NIH funds this study through a R01 grant issued to Massachusetts General Hospital.
Citation Format: Irene L. Wapnir, Kelly K. Hunt, E Shelley Hwang, Kate Smith, Peter Blumencranz, David Carr, Jorge Ferrer, Heidi Santa Cruz, Alexandra Webster, Julia Shanno, Alexander Pogrebinsky, Manna Chang, Barbara L. Smith. Feasibility study to evaluate performance of the LUM Imaging System for intraoperative detection of residual tumor in breast cancer patients receiving and not receiving neoadjuvant therapy [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr OT2-07-01.
Collapse
Affiliation(s)
- Irene L. Wapnir
- 1Stanford Cancer Institute/Stanford University, Stanford, California
| | - Kelly K. Hunt
- 2The University of Texas MD Anderson Cancer Center, Texas
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Hwang ES, Beitsch P, Blumencranz P, Carr D, Chagpar A, Clark L, Dekhne N, Dodge D, Dyess DL, Gold L, Grobmyer S, Hunt K, Karp S, Lesnikoski BA, Wapnir I, Smith BL. Clinical Impact of Intraoperative Margin Assessment in Breast-Conserving Surgery With a Novel Pegulicianine Fluorescence-Guided System: A Nonrandomized Controlled Trial. JAMA Surg 2022; 157:573-580. [PMID: 35544130 PMCID: PMC9096689 DOI: 10.1001/jamasurg.2022.1075] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Importance Positive margins following breast-conserving surgery (BCS) are often identified on standard pathology evaluation. Intraoperative assessment of the lumpectomy cavity has the potential to reduce residual disease or reexcision rate following standard of care BCS in real time. Objective To collect safety and initial efficacy data on the novel pegulicianine fluorescence-guided system (pFGS) when used to identify residual cancer in the tumor bed of female patients undergoing BCS. Design, Setting, and Participants This prospective single-arm open-label study was conducted as a nonrandomized multicenter controlled trial at 16 academic or community breast centers across the US. Female patients 18 years and older with newly diagnosed primary invasive breast cancer or ductal carcinoma in situ DCIS undergoing BCS were included, excluding those with previous breast cancer surgery and a history of dye allergies. Of 283 consecutive eligible patients recruited, 234 received a pegulicianine injection and were included in the safety analysis; of these, 230 were included in the efficacy analysis. Patients were enrolled between February 6, 2018, and April 10, 2020, and monitored for a 30-day follow-up period. Data were analyzed from April 10, 2020, to August 5, 2021. Interventions Participants received an injection of a novel imaging agent (pegulicianine) a mean (SD) of 3.2 (0.9) hours prior to surgery at a dose of 1 mg/kg. After completing standard of care (SOC) excision, pFGS was used to scan the lumpectomy cavity to guide the removal of additional shave margins. Main Outcomes and Measures Adverse events and sensitivity, specificity, and reexcision rate. Results Of 234 female patients enrolled (median [IQR] age, 62.0 [55.0-69.0] years), 230 completed the trial and 1 patient with a history of allergy to contrast agents had an anaphylactic reaction and recovered without sequelae. Correlation of pFGS with final margin status on a per-margin analysis showed a marked improvement in sensitivity over standard pathology assessment of the main lumpectomy specimen (69.4% vs 38.2%, respectively). On a per-patient level, the false-negative rate of pFGS was 23.7% (9 of 38), and sensitivity was 76.3% (29 of 38). Among 32 patients who underwent excision of pFGS-guided shaves, pFGS averted the need for reexcision in 6 (19%). Conclusions and Relevance In this pilot feasibility study, the safety profile of pegulicianine was consistent with other imaging agents used in BCS, and was associated with a reduced need for second surgery in patients who underwent intraoperative additional excision of pFGS-guided shaves. These findings support further development and clinical performance assessment of pFGS in a prospective randomized trial. Trial Registration ClinicalTrials.gov Identifier: NCT03321929.
Collapse
Affiliation(s)
- E. Shelley Hwang
- Duke Cancer Institute and Duke University Health System, Durham, North Carolina
| | | | - Peter Blumencranz
- The Comprehensive Breast Care Center, BayCare Medical Group, Clearwater, Florida
| | - David Carr
- Novant Health, Winston-Salem, North Carolina
| | | | | | | | | | - Donna L. Dyess
- Mitchell Cancer Institute, University of South Alabama, Mobile
| | | | | | - Kelly Hunt
- MD Anderson Cancer Center, Houston, Texas
| | - Stephen Karp
- Beth Israel Lahey Health, Burlington, Massachusetts
| | | | | | | |
Collapse
|
5
|
Ferrer J, Carr D, Blumencranz P, Wapnir I, Dyess D, Hwang S, Dekhne N, Dodge D, Lesnikoski BA, Hunt K, Clark P, Valente S, Lee MC, Clark L, Schlossberg B, Madden S, Rodriguez A, Smith K, Chang M, Smith B. Abstract OT2-12-03: Pivotal study of the Lum imaging system for assisting intraoperative detection of residual cancer in the tumor bed of female patients with breast cancer: The INCITE trial. Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-ot2-12-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background Breast-conserving surgery is a critical step in treatment with the goal of removing all cancer cells while minimizing the removal of healthy tissue. 15% to 25% of lumpectomy patients have positive margins and require a second surgery to achieve negative margins and reduce the risk of local recurrences. These positive margins are poorly predictive (35% PPV) of cancer left in the cavity, so most second surgeries find no residual cancer. Better detection tools are needed to guide in real-time the removal of cancer missed during the initial lumpectomy to reduce the number of second operations. The pegulicianine imaging agent is injected intravenously before surgery and its fluorescence signal is activated by proteases in tumor cells and cells at the tumor margin. The LUM Imaging System visualizes activated pegulicianine in the lumpectomy cavity via a hand-held detector and proprietary tumor detection software. This system was previously tested in multiple single-site studies and a prospective multi-site study that enrolled 234 patients and showed good ability to detect residual cancer in the lumpectomy cavity. Trial Design and Specific Aims: The current prospective, multi-center, randomized, blinded study was designed to show the clinical efficacy, system accuracy, and safety of the LUM Imaging System. It aims to demonstrate guided removal of residual cancer in the lumpectomy missed during the initial procedure and potentially reduce the rates of positive margins. This study is powered by an event-driven design that requires 70 truth-standard positive events. It is expected that approximately 390 women at fourteen medical centers across the US will be enrolled to achieve the number of events. Pegulicianine is injected 2-6 hours prior to the lumpectomy procedure. Surgeons perform standard of care (SOC) lumpectomy followed by blinded intraoperative imaging of the lumpectomy cavity with the LUM Imaging System in regions where SOC shaves will be taken. The patient is then randomized. If the random assignment is to the device arm, the surgeon is directed to excise margins that have positive LUM signal. Pathologists are blinded to the source of tissue removed (SOC vs. LUM) when conducting the pathology assessment. The amount of additional tissue volume resected is also evaluated. Patient reported outcome data is collected as a quality-of-life survey before and after the subject’s lumpectomy.Eligibility Criteria: This study seeks to enroll women with primary invasive breast cancer (IBC), ductal carcinoma in situ (DCIS) or a combination of IBC/DCIS undergoing a lumpectomy for their breast malignancy. Patients must not have a history of allergic reaction to polyethylene glycol, contrast agents, or have received neoadjuvant therapy to treat their current breast cancer. Use of blue dyes before imaging with the LUM System are not allowed. Additional detailed eligibility criteria are listed in the protocol. Accrual and Study Progress To date, 350 subjects have participated in this trial. This study is funded in part by the National Cancer Institute (5R44CA211013). This trial is registered as NCT03686215.
Citation Format: Jorge Ferrer, David Carr, Peter Blumencranz, Irene Wapnir, Donna Dyess, Shelly Hwang, Nayana Dekhne, Daleela Dodge, Beth-Ann Lesnikoski, Kelly Hunt, Patricia Clark, Stephanie Valente, Marie Catherine Lee, Lynne Clark, Brian Schlossberg, Sean Madden, Alejandra Rodriguez, Kate Smith, Manna Chang, Barbara Smith. Pivotal study of the Lum imaging system for assisting intraoperative detection of residual cancer in the tumor bed of female patients with breast cancer: The INCITE trial [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr OT2-12-03.
Collapse
|
6
|
Ferrer J, Carr D, Blumencranz P, Wapnir I, Dyess D, Hwang S, Dekhne N, Dodge D, Lesnikoski BA, Hunt K, Clark P, Valente S, Lee MC, Clark L, Schlossberg B, Madden S, Rodriguez A, Smith K, Chang M, Smith B. Abstract CT259: Pivotal Study of the LUM Imaging System for assisting intraoperative detection of residual cancer in the tumor bed of female patients with breast cancer. Cancer Res 2021. [DOI: 10.1158/1538-7445.am2021-ct259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background Breast-conserving surgery is a critical first step in treatment with the goal of removing all cancer cells while minimizing the removal of healthy tissue. 15% to 25% or more of lumpectomy patients have positive margins and require a second surgery to achieve negative margins and reduce the risk of local recurrences. These positive margins are poorly predictive (35% PPV) of cancer left in the cavity, so most second surgeries find no residual cancer. Better detection tools are needed to identify residual cancer in real time during the initial lumpectomy to reduce the number of second operations. LUM015 is a protease-activated fluorescent imaging agent that accumulates in tumor cells and tumor associated macrophages. The LUM Imaging System camera visualizes the intravenously injected LUM015 in the lumpectomy cavity via a hand-held wide field detector and proprietary tumor detection software. This imaging system was previously tested in multiple single-site studies and a large, prospective multi-site study that enrolled 234 patients and showed good ability to detect residual cancer in the lumpectomy cavity. Trial Design The current prospective, multi-center, randomized, blinded study was designed to demonstrate the clinical efficacy, system accuracy, and safety of the LUM Imaging System. It aims to identify residual cancer in the lumpectomy cavity to reduce the rates of positive margins. This study seeks to enroll women with primary invasive breast cancer (IBC), ductal carcinoma in situ (DCIS) or a combination of IBC/DCIS undergoing a lumpectomy for their breast malignancy. Approximately 310 women at 14 US medical centers will be enrolled. This study is powered by an event-driven design that requires 70 patients to be enrolled that have a ‘truth-standard positive' event, which is the identification of cancer in a protocol defined tissue type. To be eligible, patients must not have a history of allergic reaction to polyethylene glycol, intravenous contrast agents, or systemic therapies to treat their cancer. Use of blue dyes before imaging with the LUM System are not allowed. LUM015 is injected prior to the lumpectomy procedure. Surgeons perform standard of care (SOC) lumpectomy and perform blinded intraoperative imaging of the lumpectomy cavity with the LUM Imaging System in regions where SOC shaves will be taken. The patient is then randomized. If the random assignment is to the device arm, the surgeon is directed to excise margins that the LUM System indicates are positive for cancer. Pathologists are blinded to the type of tissue removed when conducting the pathology assessment. Patient reported outcome data is collected as a quality-of-life survey before and after the subject's lumpectomy. Additional detailed eligibility criteria are in the protocol. To date, 166 patients have participated in this trial. This trial is registered as NCT03686215.
Citation Format: Jorge Ferrer, David Carr, Peter Blumencranz, Irene Wapnir, Donna Dyess, Shelly Hwang, Nayana Dekhne, Daleela Dodge, Beth-Ann Lesnikoski, Kelly Hunt, Patricia Clark, Stephanie Valente, M. Catherine Lee, Lynne Clark, Brian Schlossberg, Sean Madden, Alejandra Rodriguez, Kate Smith, Manna Chang, Barbara Smith. Pivotal Study of the LUM Imaging System for assisting intraoperative detection of residual cancer in the tumor bed of female patients with breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr CT259.
Collapse
|
7
|
Russo N, Mills M, Nanda R, Baginski J, Wilson J, Allen K, Blumencranz P, Diaz R. Outcomes in ER-negative Breast Cancer Treated with Accelerated Partial Breast Irradiation Using Intracavitary Brachytherapy. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
8
|
Mills M, Liveringhouse C, Lee F, Nanda RH, Ahmed KA, Washington IR, Thapa R, Fridley BL, Blumencranz P, Extermann M, Loftus L, Balducci L, Diaz R. The prevalence of luminal B subtype is higher in older postmenopausal women with ER+/HER2- breast cancer and is associated with inferior outcomes. J Geriatr Oncol 2020; 12:219-226. [PMID: 32859560 DOI: 10.1016/j.jgo.2020.08.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2020] [Revised: 07/15/2020] [Accepted: 08/19/2020] [Indexed: 11/18/2022]
Abstract
OBJECTIVES To establish whether clinicopathologic and genomic characteristics may explain the poor prognosis associated with advanced age in ER+/HER2- breast cancer. MATERIALS AND METHODS The cohort included 271 consecutive post-menopausal patients with ER+/HER2- invasive breast cancer ages 55 years and older. Patients were categorized as "younger" (ages 55- < 75) and "older" (ages ≥75). The Kaplan-Meier method was used to estimate locoregional recurrence (LRR), recurrence-free interval (RFi), and overall survival (OS). Gene expression of tumor samples was assessed with Affymetrix Rosetta/Merck Human RSTA microarray platform. Differential gene expression analysis of tumor samples was performed using R package Limma. RESULTS 271 breast cancer patients were identified, including 186 younger and 85 older patients. Older patients had higher rates of Luminal B subtype (53% vs 34%) and lower rates of Luminal A subtype (42% vs 58%, p = 0.02). Older patients were less likely to receive chemotherapy (9% vs 40%, p < 0.001) and hormone therapy (71% vs 89%, p < 0.001). For cases of grade 1-2 disease, older patients had a higher proportion of the luminal B subtype (49% vs. 30%, p = 0.014). Age ≥ 75 predicted for inferior OS (HR = 3.06, p < 0.001). The luminal B subtype predicted for inferior OS (HR = 2.12, p = 0.014), RFi (HR 5.02, p < 0.001), and LRR (HR = 3.12, p = 0.045). There were no significant differences in individual gene expression between the two groups. CONCLUSION Women with ER+/HER2- breast cancer ≥75 years old had higher rates of the more aggressive luminal B subtype and inferior outcomes. Genomic testing of these patients should be strongly considered, and treatment should be intensified when appropriate.
Collapse
Affiliation(s)
- Matthew Mills
- Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, United States of America
| | - Casey Liveringhouse
- Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, United States of America
| | - Frank Lee
- University of South Florida Morsani College of Medicine, Tampa, FL, United States of America
| | - Ronica H Nanda
- Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, United States of America
| | - Kamran A Ahmed
- Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, United States of America
| | - Iman R Washington
- Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, United States of America
| | - Ram Thapa
- Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, United States of America
| | - Brooke L Fridley
- Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, United States of America
| | - Peter Blumencranz
- Department of Surgery, Morton Plant Hospital, Clearwater, FL, United States of America
| | - Martine Extermann
- Department of Senior Adult Oncology, Moffitt Cancer Center, Tampa, FL, United States of America
| | - Loretta Loftus
- Department of Breast Oncology, Moffitt Cancer Center, Tampa, FL, United States of America
| | - Lodovico Balducci
- Department of Senior Adult Oncology, Moffitt Cancer Center, Tampa, FL, United States of America
| | - Roberto Diaz
- Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, United States of America.
| |
Collapse
|
9
|
Ferrer J, Carr D, Wapnir I, Hunt K, Blumencranz P, Dekhne N, Dodge D, Dyess DL, Hwang S, Valente S, Clark L, Lesnikoski BA, Chagpar A, Clark P, Lee MC, Schlossberg B, Madden S, Gjylameti L, Chang M, Smith K, Smith B. Abstract CT281: Pivotal study of the LUM Imaging System for assisting intraoperative detection of residual cancer in the tumor bed of female patients with breast cancer. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-ct281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: For many women with breast cancer, breast-conserving surgery is a critical first step in treatment with the goal of removing all cancer cells while minimizing the removal of healthy tissue. 15% to 25% or more of lumpectomy patients have positive margins and require a second surgery to achieve negative margins and reduce the risk of local recurrences. These positive margins are poorly predictive (35% PPV) of cancer left in the cavity, so most second surgeries find no residual cancer. Better detection tools are needed to identify residual cancer in real time during the initial lumpectomy to reduce the number of second operations. LUM015 is a protease-activated fluorescent imaging agent that accumulates in tumor cells and tumor associated macrophages. The LUM Imaging System camera visualizes the intravenously injected LUM015 in the lumpectomy cavity via a hand-held wide field detector and proprietary tumor detection software. This imaging system was previously tested in multiple single-site studies and a large, prospective multi-site study that enrolled 234 patients and showed good ability to detect residual cancer in the lumpectomy cavity. Trial Design: The current prospective multi-center, two-arm randomized, blinded study was designed to demonstrate the clinical efficacy, system accuracy, and safety of the LUM Imaging System. It aims to identify residual cancer in the lumpectomy cavity in order to reduce the rates of positive margins. This study seeks to enroll women with confirmed primary invasive breast cancer (IBC), ductal carcinoma in situ (DCIS) or a combination of IBC/DCIS undergoing a lumpectomy for their breast malignancy. The planned enrollment is 170 women being treated at fifteen medical centers across the US. To be eligible, patients must not have a history of allergic reaction to polyethylene glycol, intravenous contrast agents, or systemic therapies to treat their cancer. Use of blue dyes before imaging with the LUM System are not allowed. LUM015 is injected prior to the lumpectomy procedure. Surgeons perform standard of care (SOC) lumpectomy and perform blinded intraoperative imaging of the lumpectomy cavity with the LUM Imaging System in any regions where SOC shaves will be taken. The patient is then randomized either the further use of device or not. If the random assignment is to the device arm, the surgeon is directed to excise margins that the LUM System indicates are positive for cancer. Pathologists are blinded to the type of tissue removed when conducting the pathology assessment. Patient reported outcome data is collected as a quality of life survey before and after the subject's surgery. Additional detailed eligibility criteria are listed in the protocol. To date, 22 subjects have participated in this trial. This trial is registered as NCT03686215.
Citation Format: Jorge Ferrer, David Carr, Irene Wapnir, Kelly Hunt, Peter Blumencranz, Nayana Dekhne, Daleela Dodge, Donna Lynn Dyess, Shelley Hwang, Stephanie Valente, Lynne Clark, Beth-Ann Lesnikoski, Anees Chagpar, Paticia Clark, Marie Catherine Lee, Brian Schlossberg, Sean Madden, Livia Gjylameti, Manna Chang, Kate Smith, Barbara Smith. Pivotal study of the LUM Imaging System for assisting intraoperative detection of residual cancer in the tumor bed of female patients with breast cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT281.
Collapse
Affiliation(s)
| | | | | | - Kelly Hunt
- 4The University of Texas M.D. Anderson Cancer Center, Houston, TX
| | - Peter Blumencranz
- 5The Comprehensive Breast Care Center of Tampa Bay (BayCare), Clearwater, FL
| | | | - Daleela Dodge
- 7Penn State Milton S. Hershey Medical Center, Hershey, PA
| | - Donna Lynn Dyess
- 8Mitchell Cancer Institute-University of South Alabama, Mobile, AL
| | | | | | - Lynne Clark
- 11CHI Franciscan Research Center, Tacoma, WA
| | | | - Anees Chagpar
- 13Yale University-Smilow Cancer Center, New Haven, CT
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Smith K, Ferrer J, Carr D, Blumencranz P, Dodge D, Dekhne N, Wapnir I, Hunt K, Gold L, Valente S, Beitsch P, Dyess D, Hwang S, Clark L, Lesnikoski BA, Chagpar A, Karp S, Schlossberg B, Gjylameti L, Smith B. Abstract OT3-06-02: Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-ot3-06-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Standard surgical techniques result in positive lumpectomy margins 20-40% of the time. These positive margins require surgical re-excision which places significant burden on the healthcare system and patients. The LUM Imaging System consists of a fluorescence-based imaging agent, a hand-held wide-field detector (LUM Imaging Device) used to image the surgical cavity walls intraoperatively in real-time after the resection of the main lumpectomy specimen, and a proprietary tumor detection algorithm that highlights regions in the tumor bed suspected to contain residual cancer. This imaging system was previously tested in a single-site clinical study. The current study is evaluating the imaging system in a multi-study, large patient cohort. Trial Design / Methods This trial (NCT03321929) is a non-randomized, open-label, multi-site trial designed to further refine the tumor detection algorithm utilized by the LUM Imaging System. This is a prospective, interventional feasibility study and is a pilot arm to a pivotal study which will evaluate the safety and efficacy of the LUM Imaging System. Up to 250 adult female breast cancer patients undergoing lumpectomies are being enrolled at sixteen medical centers across the US. LUM015, a fluorescence-based imaging agent, is injected prior to the subject’s lumpectomy procedure. Surgeons perform their standard of care lumpectomy followed by intraoperative imaging of the lumpectomy cavity with the LUM Imaging System. Specific Aims The primary objective is to assess performance characteristics of the LUM Imaging System and to refine the tumor detection algorithm. A secondary objective is to develop and refine the process of implementing the LUM Imaging System into institution-specific workflows during lumpectomies. Eligibility Criteria This study seeks to enroll women, over the age of 18 and with histologically or cytologically confirmed primary invasive breast cancer (IBC), ductal carcinoma in situ (DCIS) or a combination of IBC/DCIS undergoing a lumpectomy for their breast malignancy. In addition to be willing to follow study procedures, participating in an informed consent discussion, signing an informed consent form, and having baseline lab and screening values within protocol limits, enrolled subjects must meet the following key exclusion criteria: have no history of allergic reaction to polyethylene glycol, no history of allergic reaction to intravenous contrast agents, have not undergone any systemic therapies to treat their cancer, and will not be administered methylene blue or other dye for sentinel lymph node detection during their lumpectomy. Additional detailed eligibility criteria are listed in the protocol. Statistical Methods For categorical variables, summary tabulations of the number and percentage of patients within each category (with a category for missing data) of the parameter will be presented. For continuous variables, the number of patients, mean, median, standard deviation, minimum, and maximum values will be presented. The secondary objective will be met by evaluating a robust training and proficiency protocol for all enrolling institutions. Accrual To date, 208 subjects have participated in this LUM Imaging System trial. Contact Information Jorge Ferrer: jmferrer@lumicell.com Kate Smith: kate@lumicell.com
Citation Format: Kate Smith, Jorge Ferrer, David Carr, Peter Blumencranz, Daleela Dodge, Nayana Dekhne, Irene Wapnir, Kelly Hunt, Linsey Gold, Stephanie Valente, Peter Beitsch, Donna Dyess, Shelly Hwang, Lynne Clark, Beth-Ann Lesnikoski, Anees Chagpar, Stephen Karp, Brian Schlossberg, Livia Gjylameti, Barbara Smith. Expansion into multiple institutions for training in the use of the LUM Imaging System for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr OT3-06-02.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Kelly Hunt
- 7University of Texas at MD Anderson, Houston, TX
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Ferrer J, Carr D, Blumencranz P, Dodge D, Dekhne N, Wapnir I, Hunt K, Gold L, Valente S, Beitsch P, Dyess D, Hwang S, Clark L, Lesnikoski BA, Chagpar A, Karp S, Schlossberg B, Madden S, Chang M, Smith K, Strasfeld D, Lee WD, Smith B. Abstract P1-20-06: Results from the expansion into multiple institutions for training in the use of the LUM imaging system for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer clinical trial. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-p1-20-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Standard surgical techniques result in positive lumpectomy margins 20-40% of the time. These positive margins require surgical re-excision which places significant burden on the healthcare system and patients. The LUM Imaging System consists of a fluorescent drug, a hand-held wide-field detector (LUM Imaging Device) used to image the surgical cavity walls intraoperatively in real-time after the resection of the main lumpectomy specimen, and a proprietary tumor detection algorithm that highlights regions in the tumor bed suspected to contain residual cancer. Methods: The Intraoperative Detection of Residual Cancer in Breast Cancer trial (NCT03321929) is a non-randomized, open-label, multi-site trial. This is a prospective, interventional feasibility study and is a pilot arm to a pivotal study which will further evaluate the safety and efficacy of the LUM Imaging System. This study enrolls women, over the age of 18 and with histologically or cytologically confirmed primary invasive breast cancer (IBC), ductal carcinoma in situ (DCIS) or a combination of IBC/DCIS undergoing a lumpectomy for their breast malignancy. LUM015, a fluorescent drug, is injected prior to the subject’s lumpectomy procedure. Surgeons perform their standard of care lumpectomy followed by intraoperative imaging of the lumpectomy cavity with the LUM Imaging System. In real-time, the LUM Imaging System highlights areas within the tumor bed that may contain, residual abnormal tumor tissue. Surgeons remove additional tissue based on the guidance of the LUM Imaging System. A maximum of two additional tissue shaves may be obtained. All excised tissue specimens are evaluated by routine pathology and correlated to the output of the LUM Imaging System. Results and Discussion: Sixteen medical centers across the United States enrolled 234 subjects into this study. Preliminary data on 141 subjects has been evaluated. The median age of enrolled women undergoing surgery using the Lumicell system was 61 years old. The histology of tumor type in women evaluated in this analysis is representative of the general population, with 21% diagnosed with ductal carcinoma in-situ (DCIS), 11% diagnosed with invasive lobular carcinoma, and 64% diagnosed with invasive ductal carcinoma (with or without DCIS features present). Most women (71%) presented with a palpable mass on physical examination prior to their lumpectomy surgery. Radiological imaging prior to lumpectomy showed scattered areas of fibroglandular density in 49% of the enrolled subjects and heterogeneously dense breast tissue in 42% of the enrolled subjects. The use of the LUM Imaging System positively impacted enrolled subjects; approximately 10% of subjects (N=14) had residual tumor detected and removed from the tumor bed guided by the LUM Imaging System after the standard of care surgery was completed. Without the use of this guidance technology, tumor tissue would have been left behind in this cohort of subjects, potentially requiring additional surgical intervention or other therapy, or local recurrence. The mean absolute volume of tissue removed due to guidance by the Lumicell System was 15 cc corresponding to about 15% of the total tissue removed. The LUM Imaging System correctly identified all positive margins in 28% of subjects with a positive margin after standard of care, and directed excision of additional tissue to create a wider margin. 12% of the patients with positive margins were converted to a negative margin by removing additional tissue guided by this imaging system. Future studies are planned that will measure the sensitivity and specificity of the device.
Citation Format: Jorge Ferrer, David Carr, Peter Blumencranz, Daleela Dodge, Nayana Dekhne, Irene Wapnir, Kelly Hunt, Linsey Gold, Stephanie Valente, Peter Beitsch, Donna Dyess, Shelly Hwang, Lynne Clark, Beth-Ann Lesnikoski, Anees Chagpar, Stephen Karp, Brian Schlossberg, Sean Madden, Manna Chang, Kate Smith, David Strasfeld, W David Lee, Barbara Smith. Results from the expansion into multiple institutions for training in the use of the LUM imaging system for intraoperative detection of residual cancer in the tumor bed of female subjects with breast cancer clinical trial [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P1-20-06.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Kelly Hunt
- 7University of Texas at MD Anderson, Houston, TX
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Mills M, Liveringhouse C, Lee F, Nanda R, Ahmed K, Washington I, Thapa R, Fridley B, Blumencranz P, Extermann M, Balducci L, Diaz R. THE PREVALENCE OF LUMINAL B SUBTYPE IS HIGHER IN OLDER POSTMENOPAUSAL WOMEN WITH ER+/HER2– BREAST CANCER AND IS ASSOCIATED WITH INFERIOR OUTCOMES. J Geriatr Oncol 2019. [DOI: 10.1016/s1879-4068(19)31150-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
13
|
Brufsky AM, Crozier JA, Grady I, Lomis T, Whitworth P, Rehmus E, Srkalovic G, Lee L, Blumencranz P, Baron P, Mavromatis B, Untch S, Blumencranz L, Yoder EB, Audeh W. Abstract OT1-13-01: MammaPrint, BluePrint, and full-genome data linked with clinical data to evaluate new gene expression profiles (FLEX). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot1-13-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Genomic signatures are revolutionizing the definition, identification, and treatment of breast cancer subtypes. The ability of genomic signatures to enable fine grained stratification of breast cancers to the granular disease level is still generally untested because of the difficulties in aggregating large clinical data sets. In order to stratify breast cancers into actionable subtypes both the full genome data and clinical data must be collected for patients at scale.
DESIGN & METHODS: FLEX is designed as a novel, large-scale, population based, prospective registry. All patients with stage I-III breast cancer who receive MammaPrint (MP) or BluePrint (BP) testing on a primary breast tumor are eligible. FLEX utilizes an adaptive design which enables additional study arms at low incremental effort and cost by allowing targeted substudies to be added. Patients who are enrolled in the initial study will also be eligible for inclusion in any additional study arm where they meet all criteria. Additional study arms and substudies may be investigator-initiated.
SPECIFIC AIMS:
Primary: Create a big-data registry of full genome expression data and clinical data to investigate new gene associations with prognostic and/or predictive value.
Secondary: Generate hypotheses for targeted subset analyses and trials based on full genome data. To date the following substudies have been proposed:
DR. JENNIFER A. CROZIER, BAPTIST MD ANDERSON CANCER CENTER
(1) MP and BP in male breast cancer TYPE: SUBSTUDY; NO ADDITIONAL CONSENT (ICF) REQUIRED. ARMS: ALL (2) MP BP evaluation in breast cancer patients ≥70. TYPE: SUBSTUDY; NO ADDITIONAL ICF REQUIRED. ARMS: ALL (3) FG evaluation in ILC. TYPE: SUBSTUDY; NO ADDITIONAL ICF REQUIRED. ARMS: ALL (4,5) MP BP relation to PR positivity, Ki67. TYPE: SUBSTUDY; NO ADDITIONAL ICF REQUIRED. ARMS: ALL (6) MP BP in metaplastic breast cancer. TYPE: SUBSTUDY; NO ADDITIONAL ICF REQUIRED. ARMS: ALL
DR. ADAM M. BRUFSKY, UNIVERSITY OF PITTSBURGH MEDICAL CENTER MAGEE WOMENS HOSPITAL
(1) Response to standard chemotherapy regimens in clinically ER+/PR+/HER2+ (triple positive) patients according to BP molecular subtypes. (2) Expression signatures by response to bisphosphonates in ER+ patients receiving adjuvant therapy, or for osteoporosis after primary treatment. (3) Gene expression in breast cancer patients with obesity. TYPE: SUBSTUDY; DUAL ICF UTILIZED. ARMS: NEOADJUVANT AND ADJUVANT
DR. IAN GRADY, NORTH VALLEY BREAST CLINIC
Impact of genomic risk classification on travel time to receive breast cancer care. TYPE: SUBSTUDY; NO ADDITIONAL ICF REQUIRED. ARMS: ALL
DR. THOMAS LOMIS, VALLEY BREAST CARE
Complementary data collection for patients participating in the ODM-201 trial. FLEX provides gene expression for exploratory and signature discovery. TYPE: COMPLEMENTARY; DUAL ICF UTILIZED. ARM: NEOADJUVANT
DR. PAT WHITWORTH, NASHVILLE BREAST CENTER
Genomic reclassification of large tumors eligible to receive NCT therapy. TYPE: SUBSTUDY; NO ADDITIONAL ICF REQUIRED. ARM: NEOADJUVANT
ELIGIBILITY, ACCRUAL
FLEX will enroll a minimum of 10000 patients aged ≥18 with stage I-III breast cancer who sign ICF. Enrollment began April 2017 and 623 patients have been enrolled as of June 2018.
Citation Format: Brufsky AM, Crozier JA, Grady I, Lomis T, Whitworth P, Rehmus E, Srkalovic G, Lee L, Blumencranz P, Baron P, Mavromatis B, Untch S, Blumencranz L, Yoder EB, Audeh W, FLEX Investigators Group. MammaPrint, BluePrint, and full-genome data linked with clinical data to evaluate new gene expression profiles (FLEX) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT1-13-01.
Collapse
Affiliation(s)
- AM Brufsky
- University of Pittsburgh Medical Center Magee Womens Hospital, Pittsburgh, PA; Baptist MD Anderson Cancer Center, Jacksonville, FL; North Valley Breast Clinic, Redding, CA; Valley Breast Care, Van Nuys, CA; Nashville Breast Center, Nashville, TN; Akron General Medical Center, Akron, OH; Sparrow Cancer Center, Lansing, MI; Comprehensive Cancer Center, Palm Springs, CA; Morton Plant Hospita, Clearwater, FL; Breast & Melanoma Specialists of Charleston, Charleston, SC; Western Maryland Health Systems, Cumberland, MD; Agendia, Irvine, CA
| | - JA Crozier
- University of Pittsburgh Medical Center Magee Womens Hospital, Pittsburgh, PA; Baptist MD Anderson Cancer Center, Jacksonville, FL; North Valley Breast Clinic, Redding, CA; Valley Breast Care, Van Nuys, CA; Nashville Breast Center, Nashville, TN; Akron General Medical Center, Akron, OH; Sparrow Cancer Center, Lansing, MI; Comprehensive Cancer Center, Palm Springs, CA; Morton Plant Hospita, Clearwater, FL; Breast & Melanoma Specialists of Charleston, Charleston, SC; Western Maryland Health Systems, Cumberland, MD; Agendia, Irvine, CA
| | - I Grady
- University of Pittsburgh Medical Center Magee Womens Hospital, Pittsburgh, PA; Baptist MD Anderson Cancer Center, Jacksonville, FL; North Valley Breast Clinic, Redding, CA; Valley Breast Care, Van Nuys, CA; Nashville Breast Center, Nashville, TN; Akron General Medical Center, Akron, OH; Sparrow Cancer Center, Lansing, MI; Comprehensive Cancer Center, Palm Springs, CA; Morton Plant Hospita, Clearwater, FL; Breast & Melanoma Specialists of Charleston, Charleston, SC; Western Maryland Health Systems, Cumberland, MD; Agendia, Irvine, CA
| | - T Lomis
- University of Pittsburgh Medical Center Magee Womens Hospital, Pittsburgh, PA; Baptist MD Anderson Cancer Center, Jacksonville, FL; North Valley Breast Clinic, Redding, CA; Valley Breast Care, Van Nuys, CA; Nashville Breast Center, Nashville, TN; Akron General Medical Center, Akron, OH; Sparrow Cancer Center, Lansing, MI; Comprehensive Cancer Center, Palm Springs, CA; Morton Plant Hospita, Clearwater, FL; Breast & Melanoma Specialists of Charleston, Charleston, SC; Western Maryland Health Systems, Cumberland, MD; Agendia, Irvine, CA
| | - P Whitworth
- University of Pittsburgh Medical Center Magee Womens Hospital, Pittsburgh, PA; Baptist MD Anderson Cancer Center, Jacksonville, FL; North Valley Breast Clinic, Redding, CA; Valley Breast Care, Van Nuys, CA; Nashville Breast Center, Nashville, TN; Akron General Medical Center, Akron, OH; Sparrow Cancer Center, Lansing, MI; Comprehensive Cancer Center, Palm Springs, CA; Morton Plant Hospita, Clearwater, FL; Breast & Melanoma Specialists of Charleston, Charleston, SC; Western Maryland Health Systems, Cumberland, MD; Agendia, Irvine, CA
| | - E Rehmus
- University of Pittsburgh Medical Center Magee Womens Hospital, Pittsburgh, PA; Baptist MD Anderson Cancer Center, Jacksonville, FL; North Valley Breast Clinic, Redding, CA; Valley Breast Care, Van Nuys, CA; Nashville Breast Center, Nashville, TN; Akron General Medical Center, Akron, OH; Sparrow Cancer Center, Lansing, MI; Comprehensive Cancer Center, Palm Springs, CA; Morton Plant Hospita, Clearwater, FL; Breast & Melanoma Specialists of Charleston, Charleston, SC; Western Maryland Health Systems, Cumberland, MD; Agendia, Irvine, CA
| | - G Srkalovic
- University of Pittsburgh Medical Center Magee Womens Hospital, Pittsburgh, PA; Baptist MD Anderson Cancer Center, Jacksonville, FL; North Valley Breast Clinic, Redding, CA; Valley Breast Care, Van Nuys, CA; Nashville Breast Center, Nashville, TN; Akron General Medical Center, Akron, OH; Sparrow Cancer Center, Lansing, MI; Comprehensive Cancer Center, Palm Springs, CA; Morton Plant Hospita, Clearwater, FL; Breast & Melanoma Specialists of Charleston, Charleston, SC; Western Maryland Health Systems, Cumberland, MD; Agendia, Irvine, CA
| | - L Lee
- University of Pittsburgh Medical Center Magee Womens Hospital, Pittsburgh, PA; Baptist MD Anderson Cancer Center, Jacksonville, FL; North Valley Breast Clinic, Redding, CA; Valley Breast Care, Van Nuys, CA; Nashville Breast Center, Nashville, TN; Akron General Medical Center, Akron, OH; Sparrow Cancer Center, Lansing, MI; Comprehensive Cancer Center, Palm Springs, CA; Morton Plant Hospita, Clearwater, FL; Breast & Melanoma Specialists of Charleston, Charleston, SC; Western Maryland Health Systems, Cumberland, MD; Agendia, Irvine, CA
| | - P Blumencranz
- University of Pittsburgh Medical Center Magee Womens Hospital, Pittsburgh, PA; Baptist MD Anderson Cancer Center, Jacksonville, FL; North Valley Breast Clinic, Redding, CA; Valley Breast Care, Van Nuys, CA; Nashville Breast Center, Nashville, TN; Akron General Medical Center, Akron, OH; Sparrow Cancer Center, Lansing, MI; Comprehensive Cancer Center, Palm Springs, CA; Morton Plant Hospita, Clearwater, FL; Breast & Melanoma Specialists of Charleston, Charleston, SC; Western Maryland Health Systems, Cumberland, MD; Agendia, Irvine, CA
| | - P Baron
- University of Pittsburgh Medical Center Magee Womens Hospital, Pittsburgh, PA; Baptist MD Anderson Cancer Center, Jacksonville, FL; North Valley Breast Clinic, Redding, CA; Valley Breast Care, Van Nuys, CA; Nashville Breast Center, Nashville, TN; Akron General Medical Center, Akron, OH; Sparrow Cancer Center, Lansing, MI; Comprehensive Cancer Center, Palm Springs, CA; Morton Plant Hospita, Clearwater, FL; Breast & Melanoma Specialists of Charleston, Charleston, SC; Western Maryland Health Systems, Cumberland, MD; Agendia, Irvine, CA
| | - B Mavromatis
- University of Pittsburgh Medical Center Magee Womens Hospital, Pittsburgh, PA; Baptist MD Anderson Cancer Center, Jacksonville, FL; North Valley Breast Clinic, Redding, CA; Valley Breast Care, Van Nuys, CA; Nashville Breast Center, Nashville, TN; Akron General Medical Center, Akron, OH; Sparrow Cancer Center, Lansing, MI; Comprehensive Cancer Center, Palm Springs, CA; Morton Plant Hospita, Clearwater, FL; Breast & Melanoma Specialists of Charleston, Charleston, SC; Western Maryland Health Systems, Cumberland, MD; Agendia, Irvine, CA
| | - S Untch
- University of Pittsburgh Medical Center Magee Womens Hospital, Pittsburgh, PA; Baptist MD Anderson Cancer Center, Jacksonville, FL; North Valley Breast Clinic, Redding, CA; Valley Breast Care, Van Nuys, CA; Nashville Breast Center, Nashville, TN; Akron General Medical Center, Akron, OH; Sparrow Cancer Center, Lansing, MI; Comprehensive Cancer Center, Palm Springs, CA; Morton Plant Hospita, Clearwater, FL; Breast & Melanoma Specialists of Charleston, Charleston, SC; Western Maryland Health Systems, Cumberland, MD; Agendia, Irvine, CA
| | - L Blumencranz
- University of Pittsburgh Medical Center Magee Womens Hospital, Pittsburgh, PA; Baptist MD Anderson Cancer Center, Jacksonville, FL; North Valley Breast Clinic, Redding, CA; Valley Breast Care, Van Nuys, CA; Nashville Breast Center, Nashville, TN; Akron General Medical Center, Akron, OH; Sparrow Cancer Center, Lansing, MI; Comprehensive Cancer Center, Palm Springs, CA; Morton Plant Hospita, Clearwater, FL; Breast & Melanoma Specialists of Charleston, Charleston, SC; Western Maryland Health Systems, Cumberland, MD; Agendia, Irvine, CA
| | - EB Yoder
- University of Pittsburgh Medical Center Magee Womens Hospital, Pittsburgh, PA; Baptist MD Anderson Cancer Center, Jacksonville, FL; North Valley Breast Clinic, Redding, CA; Valley Breast Care, Van Nuys, CA; Nashville Breast Center, Nashville, TN; Akron General Medical Center, Akron, OH; Sparrow Cancer Center, Lansing, MI; Comprehensive Cancer Center, Palm Springs, CA; Morton Plant Hospita, Clearwater, FL; Breast & Melanoma Specialists of Charleston, Charleston, SC; Western Maryland Health Systems, Cumberland, MD; Agendia, Irvine, CA
| | - W Audeh
- University of Pittsburgh Medical Center Magee Womens Hospital, Pittsburgh, PA; Baptist MD Anderson Cancer Center, Jacksonville, FL; North Valley Breast Clinic, Redding, CA; Valley Breast Care, Van Nuys, CA; Nashville Breast Center, Nashville, TN; Akron General Medical Center, Akron, OH; Sparrow Cancer Center, Lansing, MI; Comprehensive Cancer Center, Palm Springs, CA; Morton Plant Hospita, Clearwater, FL; Breast & Melanoma Specialists of Charleston, Charleston, SC; Western Maryland Health Systems, Cumberland, MD; Agendia, Irvine, CA
| | | |
Collapse
|
14
|
Blumencranz P, Habibi M, Treece T, Blumencranz L, Yoder E, Audeh W, Carter E, McNaughton L, Roussos J, Shivers S, Acs G, Cox C, MINT Investigators G. Abstract PD8-04: Neoadjuvant chemotherapy for breast cancer: Nodal downstaging is highly correlated with pathological complete response. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd8-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Neoadjuvant chemotherapy (NAC) is employed in patients with larger tumors to attempt to downstage locally advanced cancers to allow breast conservation and to assess in vivo tumor response. The Multi-Institutional Neoadjuvant Therapy MammaPrint Project I (MINT) study asked a secondary question of whether complete nodal downstaging could also be achieved with NAC.
Methods: This analysis included 147 eligible invasive breast cancer patients with high tumor burdens, classified as cT2-4N0-3M0 (T2 greater than 3.5cm if N0). Patients who had a positive core biopsy and/or fine needle aspiration (FNA) on an axillary node prior to starting NAC were included in this analysis. Those who had a surgical sentinel lymph node biopsy were not included. Nodal involvement was established following neoadjuvant treatment by axillary lymph node dissection (ALND).
Results: This population was 54% postmenopausal, average age 53 yrs (range 25 to 80 yrs). Tumor characteristics were 91% invasive ductal carcinoma; 65% T2, 29% T3, 6% T4; 87% LN1, 13% LN2-3; 3% low grade, 38% intermediate grade, 59% high grade; 65% ER-positive, 49% PR-positive, and 28% HER2-positive by immunohistochemistry; 84% High Risk (HR) and 16% Low Risk (LR) by MammaPrint (MP). After NAC, 45% (66/147) of these LN-positive patients were down-staged to ypN0 and also achieved a complete pathological response in the primary tumor. The potential for down-staging was inversely-related to tumor burden, where 47% (60/128) of N1, 35% (6/17) of N2, and 0% (0/2) of N3 patients were down-staged to ypN0. There were 3 patients who were down-staged (2 N2 to N1, and 1 N3 to N2), but not to ypN0. At surgery, 34% (44/128) of patients had no change, and 19% (24/129) progressed in LN staging.
Pre vs Post NAC Nodal StagePre NAC Nodal StageypN0ypN1ypN2ypN3TotalcN16044222128cN2626317cN3 112Total6646296147
Conclusions: We confirmed that upon achieving a complete response of the primary tumor that there was also a pathologic complete response in the LN. About 53% of patients had no change or progression of LN involvement following NAC.
Citation Format: Blumencranz P, Habibi M, Treece T, Blumencranz L, Yoder E, Audeh W, Carter E, McNaughton L, Roussos J, Shivers S, Acs G, Cox C, MINT Investigators Group. Neoadjuvant chemotherapy for breast cancer: Nodal downstaging is highly correlated with pathological complete response [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD8-04.
Collapse
Affiliation(s)
- P Blumencranz
- Morton Plant Hospital, Clearwater, FL; Johns Hopkins Breast Center at Bayview, Baltimore, MD; Agendia, Inc, Irvine, CA; University of South Florida, Tampa, FL; Florida Hospital Tampa, Tampa, FL
| | - M Habibi
- Morton Plant Hospital, Clearwater, FL; Johns Hopkins Breast Center at Bayview, Baltimore, MD; Agendia, Inc, Irvine, CA; University of South Florida, Tampa, FL; Florida Hospital Tampa, Tampa, FL
| | - T Treece
- Morton Plant Hospital, Clearwater, FL; Johns Hopkins Breast Center at Bayview, Baltimore, MD; Agendia, Inc, Irvine, CA; University of South Florida, Tampa, FL; Florida Hospital Tampa, Tampa, FL
| | - L Blumencranz
- Morton Plant Hospital, Clearwater, FL; Johns Hopkins Breast Center at Bayview, Baltimore, MD; Agendia, Inc, Irvine, CA; University of South Florida, Tampa, FL; Florida Hospital Tampa, Tampa, FL
| | - E Yoder
- Morton Plant Hospital, Clearwater, FL; Johns Hopkins Breast Center at Bayview, Baltimore, MD; Agendia, Inc, Irvine, CA; University of South Florida, Tampa, FL; Florida Hospital Tampa, Tampa, FL
| | - W Audeh
- Morton Plant Hospital, Clearwater, FL; Johns Hopkins Breast Center at Bayview, Baltimore, MD; Agendia, Inc, Irvine, CA; University of South Florida, Tampa, FL; Florida Hospital Tampa, Tampa, FL
| | - E Carter
- Morton Plant Hospital, Clearwater, FL; Johns Hopkins Breast Center at Bayview, Baltimore, MD; Agendia, Inc, Irvine, CA; University of South Florida, Tampa, FL; Florida Hospital Tampa, Tampa, FL
| | - L McNaughton
- Morton Plant Hospital, Clearwater, FL; Johns Hopkins Breast Center at Bayview, Baltimore, MD; Agendia, Inc, Irvine, CA; University of South Florida, Tampa, FL; Florida Hospital Tampa, Tampa, FL
| | - J Roussos
- Morton Plant Hospital, Clearwater, FL; Johns Hopkins Breast Center at Bayview, Baltimore, MD; Agendia, Inc, Irvine, CA; University of South Florida, Tampa, FL; Florida Hospital Tampa, Tampa, FL
| | - S Shivers
- Morton Plant Hospital, Clearwater, FL; Johns Hopkins Breast Center at Bayview, Baltimore, MD; Agendia, Inc, Irvine, CA; University of South Florida, Tampa, FL; Florida Hospital Tampa, Tampa, FL
| | - G Acs
- Morton Plant Hospital, Clearwater, FL; Johns Hopkins Breast Center at Bayview, Baltimore, MD; Agendia, Inc, Irvine, CA; University of South Florida, Tampa, FL; Florida Hospital Tampa, Tampa, FL
| | - C Cox
- Morton Plant Hospital, Clearwater, FL; Johns Hopkins Breast Center at Bayview, Baltimore, MD; Agendia, Inc, Irvine, CA; University of South Florida, Tampa, FL; Florida Hospital Tampa, Tampa, FL
| | - Group MINT Investigators
- Morton Plant Hospital, Clearwater, FL; Johns Hopkins Breast Center at Bayview, Baltimore, MD; Agendia, Inc, Irvine, CA; University of South Florida, Tampa, FL; Florida Hospital Tampa, Tampa, FL
| |
Collapse
|
15
|
Blumencranz LE, Treece T, Ellis D, Barlowe K, Blumencranz P, Audeh W. Abstract P6-13-06: Not presented. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-13-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was not presented at the symposium.
Collapse
Affiliation(s)
- LE Blumencranz
- University of Miami, Miami, FL; Agendia, Irvine, CA; Morton Plant Hospital, Clearwater, FL
| | - T Treece
- University of Miami, Miami, FL; Agendia, Irvine, CA; Morton Plant Hospital, Clearwater, FL
| | - D Ellis
- University of Miami, Miami, FL; Agendia, Irvine, CA; Morton Plant Hospital, Clearwater, FL
| | - K Barlowe
- University of Miami, Miami, FL; Agendia, Irvine, CA; Morton Plant Hospital, Clearwater, FL
| | - P Blumencranz
- University of Miami, Miami, FL; Agendia, Irvine, CA; Morton Plant Hospital, Clearwater, FL
| | - W Audeh
- University of Miami, Miami, FL; Agendia, Irvine, CA; Morton Plant Hospital, Clearwater, FL
| |
Collapse
|
16
|
Cox CE, Russell S, Prowler V, Carter E, Beard A, Mehindru A, Blumencranz P, Allen K, Portillo M, Whitworth P, Funk K, Barone J, Norton D, Schroeder J, Police A, Lin E, Combs F, Schnabel F, Toth H, Lee J, Anglin B, Nguyen M, Canavan L, Laidley A, Warden MJ, Prati R, King J, Shivers SC. A Prospective, Single Arm, Multi-site, Clinical Evaluation of a Nonradioactive Surgical Guidance Technology for the Location of Nonpalpable Breast Lesions during Excision. Ann Surg Oncol 2016; 23:3168-74. [DOI: 10.1245/s10434-016-5405-y] [Citation(s) in RCA: 65] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2016] [Indexed: 11/18/2022]
|
17
|
Cox CE, Prati R, Blumencranz P, Allen K, Banull C, Cline M, Howard T, Portillo M, Whitworth P, Funk K, Police A, Lin E, Combs F, Anglin B, King J, Shivers SC. Abstract P3-13-08: A prospective, single-arm, multi-site, clinical evaluation of the SAVI SCOUT® surgical guidance system for the location of non-palpable breast lesions during excision. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-13-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background and Objectives: The standard preoperative technique for localizing non-palpable breast lesions is wire localization (WL). Radioactive seed localization (RSL) is an alternative approach that addresses a number of clear disadvantages associated with WL but, the adoption of RSL has been impacted by considerable regulatory requirements for the handling of radioactive materials. To advance the progress made with RSL and eliminate issues associated with radioactive components, the SAVI SCOUT® surgical guidance system was developed. SAVI SCOUT is an FDA-cleared medical device that utilizes non-radioactive electromagnetic wave technology to provide real-time guidance during excisional breast procedures. The purpose of this study is to evaluate the performance of SAVI SCOUT in guiding the removal of non-palpable breast lesions.
Methods: Following a 50 patient pilot study that showed SAVI SCOUT to be safe and effective, IRB approval was granted for this prospective, single-arm, multi-site study for women with a non-palpable breast lesion. Pts underwent localization and excision with the SAVI SCOUT system, which consists of an electromagnetic wave reflective device (reflector), handpiece and console. Using mammographic or ultrasound guidance, the reflector was implanted into the target tissue. Before making an incision, the surgeon used the handpiece, which emits electromagnetic waves and infrared light, to detect the location of the reflector and subsequently plan the surgical incision. During the procedure, the surgeon used the handpiece to guide the localization and removal of the reflector along with the surrounding breast tissue. The console provides audible feedback of reflector proximity to the handpiece. Successful reflector placement, localization and retrieval were the primary endpoints.
Results: A total of 61 pts have participated in the study to date, along with 7 surgeons and 9 radiologists across 6 institutions. The reflectors were successfully placed in all pts, including 27 under mammographic guidance and 34 under ultrasound guidance. In 28 cases, the reflectors were placed on the same day as surgery. Otherwise, the reflectors were placed up to 7 days (average 2.9 days) before surgery. Thirteen pts underwent excisional biopsy and 48 pts had a lumpectomy. The intended lesion and reflector were successfully removed in all pts. Reflector migration did not occur and no adverse events occurred. Final pathology is currently available for 52 pts: 8/10 excisional biopsy pts had no invasive or in situ carcinoma identified. For pts with cancer and complete data, 39/39 had clear margins, but one patient was recommended for re-excision due to a close margin (1 mm) for DCIS.
Conclusions: The preliminary data from this prospective, multi-site study show that real-time surgical guidance with SAVI SCOUT is an accurate technique for directing the removal of non-palpable breast lesions and is reproducible at multiple clinical sites. At present, the study has yielded 100% surgical success with a re-excision rate of 3.0%. Ongoing accrual to this clinical evaluation study will validate these findings with planned enrollment of 150 pts at up to 15 total sites.
Citation Format: Cox CE, Prati R, Blumencranz P, Allen K, Banull C, Cline M, Howard T, Portillo M, Whitworth P, Funk K, Police A, Lin E, Combs F, Anglin B, King J, Shivers SC. A prospective, single-arm, multi-site, clinical evaluation of the SAVI SCOUT® surgical guidance system for the location of non-palpable breast lesions during excision. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-13-08.
Collapse
Affiliation(s)
- CE Cox
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - R Prati
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - P Blumencranz
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - K Allen
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - C Banull
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - M Cline
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - T Howard
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - M Portillo
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - P Whitworth
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - K Funk
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - A Police
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - E Lin
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - F Combs
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - B Anglin
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - J King
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| | - SC Shivers
- University of South Florida Breast Health Program, Tampa, FL; Morton Plant Mease Hospital, Clearwater, FL; Nashville Breast Center, Nashville, TN; Pink Lotus Breast Center, Beverly Hills, CA; UC Irvine Health Pacific Breast Care Center, Irvine, CA; Medical Center of Plano Complete Breast Care, Plano, TX
| |
Collapse
|
18
|
Cox CE, Blumencranz P, Saez R, Wesolowski R, Dooley W, Stork-Sloots L, de Snoo F, Untch S, Avisar E. Abstract OT3-2-02: MINT I: Multi-Institutional Neo-adjuvant Therapy, MammaPrint Project I. Cancer Res 2015. [DOI: 10.1158/1538-7445.sabcs14-ot3-2-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Women with locally advanced breast cancer (LABC) are often treated with neo-adjuvant chemotherapy to reduce the size of the tumor prior to surgery, to enable breast conserving surgery and to observe the clinical effect of therapy in real time. Studies have shown that the 25–27% of individuals who have a pathologic complete response (pCR) to neoadjuvant therapy have a survival advantage of 80% in 5 years, which is double the expected survival of the remaining patients without pCR. If patients who are likely to show a pCR could be identified prior to initiation of therapy, it would enable more informed treatment decisions – patients likely to respond would be served well by current neoadjuvant chemotherapy protocols, while those unlikely to respond may be better suited to innovative new strategies for drug discovery [von Minckwitz et al. JCO 2006]. Genomic assays, which are widely used to provide prognostic and predictive information in early breast cancer, have the potential to provide information on the likelihood of a patient with LABC responding to neo-adjuvant therapy [Glück et al. BRCRT2013].
Trial design:
MINT I is a prospective study designed to test the ability of molecular profiling, as well as traditional pathologic and clinical prognostic factors, to predict response to neo-adjuvant chemotherapy in patients with LABC. MammaPrint risk profile, BluePrint molecular subtyping profile, TargetPrint estrogen receptor (ER), progesterone receptor (PR) and HER2 single gene readout, and TheraPrint Research Gene Panel will be analyzed on a fresh tumor specimen using the whole genome array. Patients will receive neo-adjuvant chemotherapy pre-specified in the protocol. Response will be measured centrally. pCR is defined as the absence of invasive carcinoma in both the breast and axilla at microscopic examination of the resection specimen, regardless of the presence of carcinoma in situ.
Eligibility:
The study will include women ≥18 years with histologically-proven invasive breast cancer T2 (≥3.5cm)-T4, N0M0 or T2-T4N1M0, adequate bone marrow reserves and normal renal and hepatic function who signed an IRB approved informed consent.
Objectives:
The objectives of the study are to:
1. Determine the predictive power of MammaPrint and BluePrint for sensitivity to neo-adjuvant chemotherapy as measured by pCR.
2. Compare TargetPrint ER, PR and HER2 with local and centralized IHC and/or CISH/FISH assessment.
3. Identify correlations between TheraPrint and response to neo-adjuvant chemotherapy.
4. Identify and/or validate predictive gene expression profiles of clinical response or resistance to neo-adjuvant chemotherapy.
5. Compare BluePrint with IHC-based subtype classification.
Statistical methods:
Standard statistical tests such as the Pearson Chi-square test will be used to characterize and evaluate the relationship between chemoresponsiveness and gene expression patterns.
Accrual:
A total of 226 eligible patients will be enrolled from multiple institutions. To date (June 06, 2014), 103 patients have been enrolled.
Citation Format: Charles E Cox, Peter Blumencranz, Ruben Saez, Robert Wesolowski, William Dooley, Lisette Stork-Sloots, Femke de Snoo, Sarah Untch, Eli Avisar. MINT I: Multi-Institutional Neo-adjuvant Therapy, MammaPrint Project I [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr OT3-2-02.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Eli Avisar
- 7Miller School of Medicine, University of Miami
| |
Collapse
|
19
|
Cox CE, Blumencranz P, Saez R, Wesolowski R, Stork-Sloots L, Gibson J, de Snoo F, Avisar E. Abstract OT1-2-01: MINT I: Multi-institutional neo-adjuvant therapy, MammaPrint project I. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-ot1-2-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Women with locally advanced breast cancer (LABC) are often treated with neo-adjuvant chemotherapy to reduce the size of the tumor prior to surgery, to enable breast conserving surgery and to observe the clinical effect of therapy in real time. Studies have shown that the 25–27% of individuals who have a pathologic complete response (pCR) to neoadjuvant therapy have a survival advantage of 80% in 5 years, which is double the expected survival of the remaining patients without pCR. If patients who are likely to show a pCR could be identified prior to initiation of therapy, it would enable more informed treatment decisions – patients likely to respond would be served well by current neoadjuvant chemotherapy protocols, while those unlikely to respond may be better suited to innovative new strategies for drug discovery [von Minckwitz et al. JCO 2006]. Genomic assays, which are widely used to provide prognostic and predictive information in early breast cancer, have the potential to provide information on the likelihood of a patient with LABC responding to neo-adjuvant therapy [Glück et al. ASCO 2012].
Trial design: MINT I is a prospective study designed to test the ability of molecular profiling, as well as traditional pathologic and clinical prognostic factors, to predict response to neo-adjuvant chemotherapy in patients with LABC. MammaPrint risk profile, BluePrint molecular subtyping profile, TargetPrint estrogen receptor (ER), progesterone receptor (PR) and HER2 single gene readout, and TheraPrint Research Gene Panel will be analyzed on a fresh tumor specimen using the whole genome array. Patients will receive neo-adjuvant chemotherapy pre-specified in the protocol. Response will be measured centrally. pCR is defined as the absence of invasive carcinoma in both the breast and axilla at microscopic examination of the resection specimen, regardless of the presence of carcinoma in situ.
Eligibility: The study will include women ≥18 years with histologically-proven invasive breast cancer T2 (≥3.5cm)-T4, N0M0 or T2-T4N1M0, adequate bone marrow reserves and normal renal and hepatic function who signed an IRB approved informed consent.
Objectives: The objectives of the study are to:
1. Determine the predictive power of MammaPrint and BluePrint for sensitivity to neo-adjuvant chemotherapy as measured by pCR.
2. Compare TargetPrint ER, PR and HER2 with local and centralized IHC and/or CISH/FISH assessment.
3. Identify correlations between TheraPrint and response to neo-adjuvant chemotherapy.
4. Identify and/or validate predictive gene expression profiles of clinical response or resistance to neo-adjuvant chemotherapy.
5. Compare BluePrint with IHC-based subtype classification.
Statistical methods: Standard statistical tests such as the Pearson Chi-square test will be used to characterize and evaluate the relationship between chemoresponsiveness and gene expression patterns.
Accrual: A total of 226 eligible patients will be enrolled from multiple institutions. To date (June 06, 2013), 57 patients have been enrolled.
Clinical trial registry number: NCT01501487.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr OT1-2-01.
Collapse
Affiliation(s)
- CE Cox
- University of South Florida, Tampa, FL; Morton Plant Hospital, Clearwater, FL; Plano Cancer Institute, Plano, TX; Ohio State University, Columbus, OH; Agendia NV, Amsterdam, Netherlands; Agendia Inc, Irvine, CA; Miller School of Medicine, University of Miami, Miami, FL
| | - P Blumencranz
- University of South Florida, Tampa, FL; Morton Plant Hospital, Clearwater, FL; Plano Cancer Institute, Plano, TX; Ohio State University, Columbus, OH; Agendia NV, Amsterdam, Netherlands; Agendia Inc, Irvine, CA; Miller School of Medicine, University of Miami, Miami, FL
| | - R Saez
- University of South Florida, Tampa, FL; Morton Plant Hospital, Clearwater, FL; Plano Cancer Institute, Plano, TX; Ohio State University, Columbus, OH; Agendia NV, Amsterdam, Netherlands; Agendia Inc, Irvine, CA; Miller School of Medicine, University of Miami, Miami, FL
| | - R Wesolowski
- University of South Florida, Tampa, FL; Morton Plant Hospital, Clearwater, FL; Plano Cancer Institute, Plano, TX; Ohio State University, Columbus, OH; Agendia NV, Amsterdam, Netherlands; Agendia Inc, Irvine, CA; Miller School of Medicine, University of Miami, Miami, FL
| | - L Stork-Sloots
- University of South Florida, Tampa, FL; Morton Plant Hospital, Clearwater, FL; Plano Cancer Institute, Plano, TX; Ohio State University, Columbus, OH; Agendia NV, Amsterdam, Netherlands; Agendia Inc, Irvine, CA; Miller School of Medicine, University of Miami, Miami, FL
| | - J Gibson
- University of South Florida, Tampa, FL; Morton Plant Hospital, Clearwater, FL; Plano Cancer Institute, Plano, TX; Ohio State University, Columbus, OH; Agendia NV, Amsterdam, Netherlands; Agendia Inc, Irvine, CA; Miller School of Medicine, University of Miami, Miami, FL
| | - F de Snoo
- University of South Florida, Tampa, FL; Morton Plant Hospital, Clearwater, FL; Plano Cancer Institute, Plano, TX; Ohio State University, Columbus, OH; Agendia NV, Amsterdam, Netherlands; Agendia Inc, Irvine, CA; Miller School of Medicine, University of Miami, Miami, FL
| | - E Avisar
- University of South Florida, Tampa, FL; Morton Plant Hospital, Clearwater, FL; Plano Cancer Institute, Plano, TX; Ohio State University, Columbus, OH; Agendia NV, Amsterdam, Netherlands; Agendia Inc, Irvine, CA; Miller School of Medicine, University of Miami, Miami, FL
| |
Collapse
|
20
|
Cox C, Blumencranz P, Reintgen D, Saez R, Howard N, Gibson J, Stork-Sloots L, Glück S. Abstract OT3-4-02: MINT I: Multi- Institutional Neo-adjuvant Therapy, MammaPrint Project I. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-ot3-4-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Women with locally advanced breast cancer (LABC) are often treated with neo-adjuvant chemotherapy to reduce the size of the tumor prior to surgery, to enable breast conserving surgery and to observe the clinical effect of therapy in real time. Studies have shown that the 25–27% of individuals who have a pathologic complete response (pCR) to neoadjuvant therapy have a survival advantage of 80% in 5 years, which is double the expected survival of the remaining patients without pCR. If patients who are likely to show a pCR could be identified prior to initiation of therapy, it would enable more informed treatment decisions – patients likely to respond would be served well by current neoadjuvant chemotherapy protocols, while those unlikely to respond may be better suited to innovative new strategies for drug discovery [von Minckwitz et al. JCO 2006]. Genomics assays, which are widely used to provide prognostic and predictive information in early breast cancer, have the potential to provide information on the likelihood of a patient with LABC responding to neo-adjuvant therapy [Glück et al. ASCO 2012].
Trial design: MINT I is a prospective study designed to test the ability of molecular profiling, as well as traditional pathologic and clinical prognostic factors, to predict responsiveness to neo-adjuvant chemotherapy in patients with LABC. MammaPrint risk profile, BluePrint molecular subtyping profile, TargetPrint estrogen receptor (ER), progesterone receptor (PR) and HER2 single gene readout, and the 56-gene TheraPrint Research Gene Panel will be analyzed on a fresh tumor specimen using the whole genome array. Patients will receive neo-adjuvant chemotherapy pre-specified in the protocol. Response will be measured centrally. pCR is defined as the absence of invasive carcinoma in both the breast and axilla at microscopic examination of the resection specimen, regardless of the presence of carcinoma in situ.
Eligibility: The study will include women ≥18 years with histologically-proven invasive breast cancer T2 (≥3.5cm)-T4, N0M0 or T2-T4N1M0, adequate bone marrow reserves and normal renal and hepatic function who signed an IRB approved informed consent.
Objectives: The objectives of the study are to: 1. Determine the predictive power of MammaPrint and BluePrint for sensitivity to neo-adjuvant chemotherapy as measured by pCR.2. Compare TargetPrint ER, PR and HER2 with local and centralized IHC and/or CISH/FISH assessment.3. Identify correlations between TheraPrint and response to neo-adjuvant chemotherapy.4. Identify and/or validate predictive gene expression profiles of clinical response or resistance to neo-adjuvant chemotherapy.5. Compare BluePrint with IHC-based subtype classification.
Statistical methods: Standard statistical tests such as the Pearson Chi-square test will be used to characterize and evaluate the relationship between chemoresponsiveness and gene expression patterns.
Accrual: A total of 226 eligible patients will be enrolled from multiple institutions. To date (June 06, 2012), 31 patients have been enrolled.
Clinical trial registry number: NCT01501487.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr OT3-4-02.
Collapse
Affiliation(s)
- C Cox
- University of South Florida; Morton Plant Hospital; Florida Hospital North Pinellas; Plano Cancer Institute; Agendia Inc; Agendia NV; Miller School of Medicine, University of Miami
| | - P Blumencranz
- University of South Florida; Morton Plant Hospital; Florida Hospital North Pinellas; Plano Cancer Institute; Agendia Inc; Agendia NV; Miller School of Medicine, University of Miami
| | - D Reintgen
- University of South Florida; Morton Plant Hospital; Florida Hospital North Pinellas; Plano Cancer Institute; Agendia Inc; Agendia NV; Miller School of Medicine, University of Miami
| | - R Saez
- University of South Florida; Morton Plant Hospital; Florida Hospital North Pinellas; Plano Cancer Institute; Agendia Inc; Agendia NV; Miller School of Medicine, University of Miami
| | - N Howard
- University of South Florida; Morton Plant Hospital; Florida Hospital North Pinellas; Plano Cancer Institute; Agendia Inc; Agendia NV; Miller School of Medicine, University of Miami
| | - J Gibson
- University of South Florida; Morton Plant Hospital; Florida Hospital North Pinellas; Plano Cancer Institute; Agendia Inc; Agendia NV; Miller School of Medicine, University of Miami
| | - L Stork-Sloots
- University of South Florida; Morton Plant Hospital; Florida Hospital North Pinellas; Plano Cancer Institute; Agendia Inc; Agendia NV; Miller School of Medicine, University of Miami
| | - S Glück
- University of South Florida; Morton Plant Hospital; Florida Hospital North Pinellas; Plano Cancer Institute; Agendia Inc; Agendia NV; Miller School of Medicine, University of Miami
| |
Collapse
|
21
|
Chagpar AB, Blumencranz P, Whitworth PW, Deck KB, Rosenberg A, Simmons RM, Reintgen DS, Beitsch P, Saha S, Julian TB. Use of intraoperative breast cancer sentinel lymph node (SLN) assay to predict of ≥4 positive (+) lymph nodes (LN). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
530 Background: Predicting which patients will have ≥4 +LN and may need radiation therapy affects immediate breast reconstruction. We hypothesized that model s to predict the likelihood of ≥4+LN may be improved by incorporation of quantitative real time RT-PCR analysis of SLN. Methods: 728 patients were enrolled in 2 prospective studies of the GeneSearch BLN Assay (Veridex LLC) for SLN metastases. 205 (28.2%) were found to have +SLN by hematoxylin-eosin staining. Of these, 115 pts (15.8%) had tumors ≤5 cm in size with >4 total LN removed, forming the cohort of interest for this study. Quantitative cycle times (CT) for mammaglobin (MG) and CK19 were correlated with finding ≥4+LN on final pathology. Results: Median tumor size was 2.0 cm (range; 0.2–5.0 cm). Median number of SLN removed was 3 (range; 1–11). 18 patients (15.7%) had ≥4 +LN on final pathology. Median CT for MG was 29.1 (interquartile range (IQR): 24.7–39.0) in patients with <4 +LN vs. 21.4 (IQR: 18.5–26.8) in those with ≥4 +LN, p<0.001. Median CT for CK19 was 23.7 (IQR: 20.9–28.2) in patients with <4 +LN vs. 19.6 (IQR: 17.8–20.7) in those with ≥4 +LN, p<0.001. Tumor size ≥2cm, proportion of SLN+ >50%, MG CT <25.8 and CK19 <20.8 were correlated with ≥4 +LN on final pathology. On multivariate analysis, tumor size, MG CT and CK19 CT were significant (see table). A simplified CPR was created with 1 point given if tumor size was ≥2cm, 1 point if MG CT <25.8 and 2 points if CK19 CT<20.8. Of the 24 patients (20.9%) with 0 points, only 1 (4.2%) had ≥4 +LN; of the 12 patients (10.4%) with 3 points, 8 (66.7%) had ≥4 +LN on final pathology, p<0.001. Area under the receiver-operator curve was 86.2% (95% CI: 76.1%-96.2%). Conclusions: Intraoperative quantitative RT-PCR of SLN improves prediction of ≥4 +LN; further validation of this model will have clinical utility regarding the use of immediate, delayed, or delayed-immediate reconstruction approaches. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- A. B. Chagpar
- University of Louisville, Louisville, KY; Morton Plant Mease Healthcare, Clearwater, FL; Nashville Breast Center, Nashville, TN; South Orange County Surgical Medical Group, Laguna Hills, CA; Jefferson University Hospital, Philadelphia, PA; Weill-Cornell Breast Center, New York, NY; Lakeland Regional Medical Center, Lakeland, FL; Dallas Surgical Group, Dallas, TX; McLaren Regional Medical Center, Flint, MI; Allegheny General Hospital, Allegheny Cancer Center, Pittsburgh, PA
| | - P. Blumencranz
- University of Louisville, Louisville, KY; Morton Plant Mease Healthcare, Clearwater, FL; Nashville Breast Center, Nashville, TN; South Orange County Surgical Medical Group, Laguna Hills, CA; Jefferson University Hospital, Philadelphia, PA; Weill-Cornell Breast Center, New York, NY; Lakeland Regional Medical Center, Lakeland, FL; Dallas Surgical Group, Dallas, TX; McLaren Regional Medical Center, Flint, MI; Allegheny General Hospital, Allegheny Cancer Center, Pittsburgh, PA
| | - P. W. Whitworth
- University of Louisville, Louisville, KY; Morton Plant Mease Healthcare, Clearwater, FL; Nashville Breast Center, Nashville, TN; South Orange County Surgical Medical Group, Laguna Hills, CA; Jefferson University Hospital, Philadelphia, PA; Weill-Cornell Breast Center, New York, NY; Lakeland Regional Medical Center, Lakeland, FL; Dallas Surgical Group, Dallas, TX; McLaren Regional Medical Center, Flint, MI; Allegheny General Hospital, Allegheny Cancer Center, Pittsburgh, PA
| | - K. B. Deck
- University of Louisville, Louisville, KY; Morton Plant Mease Healthcare, Clearwater, FL; Nashville Breast Center, Nashville, TN; South Orange County Surgical Medical Group, Laguna Hills, CA; Jefferson University Hospital, Philadelphia, PA; Weill-Cornell Breast Center, New York, NY; Lakeland Regional Medical Center, Lakeland, FL; Dallas Surgical Group, Dallas, TX; McLaren Regional Medical Center, Flint, MI; Allegheny General Hospital, Allegheny Cancer Center, Pittsburgh, PA
| | - A. Rosenberg
- University of Louisville, Louisville, KY; Morton Plant Mease Healthcare, Clearwater, FL; Nashville Breast Center, Nashville, TN; South Orange County Surgical Medical Group, Laguna Hills, CA; Jefferson University Hospital, Philadelphia, PA; Weill-Cornell Breast Center, New York, NY; Lakeland Regional Medical Center, Lakeland, FL; Dallas Surgical Group, Dallas, TX; McLaren Regional Medical Center, Flint, MI; Allegheny General Hospital, Allegheny Cancer Center, Pittsburgh, PA
| | - R. M. Simmons
- University of Louisville, Louisville, KY; Morton Plant Mease Healthcare, Clearwater, FL; Nashville Breast Center, Nashville, TN; South Orange County Surgical Medical Group, Laguna Hills, CA; Jefferson University Hospital, Philadelphia, PA; Weill-Cornell Breast Center, New York, NY; Lakeland Regional Medical Center, Lakeland, FL; Dallas Surgical Group, Dallas, TX; McLaren Regional Medical Center, Flint, MI; Allegheny General Hospital, Allegheny Cancer Center, Pittsburgh, PA
| | - D. S. Reintgen
- University of Louisville, Louisville, KY; Morton Plant Mease Healthcare, Clearwater, FL; Nashville Breast Center, Nashville, TN; South Orange County Surgical Medical Group, Laguna Hills, CA; Jefferson University Hospital, Philadelphia, PA; Weill-Cornell Breast Center, New York, NY; Lakeland Regional Medical Center, Lakeland, FL; Dallas Surgical Group, Dallas, TX; McLaren Regional Medical Center, Flint, MI; Allegheny General Hospital, Allegheny Cancer Center, Pittsburgh, PA
| | - P. Beitsch
- University of Louisville, Louisville, KY; Morton Plant Mease Healthcare, Clearwater, FL; Nashville Breast Center, Nashville, TN; South Orange County Surgical Medical Group, Laguna Hills, CA; Jefferson University Hospital, Philadelphia, PA; Weill-Cornell Breast Center, New York, NY; Lakeland Regional Medical Center, Lakeland, FL; Dallas Surgical Group, Dallas, TX; McLaren Regional Medical Center, Flint, MI; Allegheny General Hospital, Allegheny Cancer Center, Pittsburgh, PA
| | - S. Saha
- University of Louisville, Louisville, KY; Morton Plant Mease Healthcare, Clearwater, FL; Nashville Breast Center, Nashville, TN; South Orange County Surgical Medical Group, Laguna Hills, CA; Jefferson University Hospital, Philadelphia, PA; Weill-Cornell Breast Center, New York, NY; Lakeland Regional Medical Center, Lakeland, FL; Dallas Surgical Group, Dallas, TX; McLaren Regional Medical Center, Flint, MI; Allegheny General Hospital, Allegheny Cancer Center, Pittsburgh, PA
| | - T. B. Julian
- University of Louisville, Louisville, KY; Morton Plant Mease Healthcare, Clearwater, FL; Nashville Breast Center, Nashville, TN; South Orange County Surgical Medical Group, Laguna Hills, CA; Jefferson University Hospital, Philadelphia, PA; Weill-Cornell Breast Center, New York, NY; Lakeland Regional Medical Center, Lakeland, FL; Dallas Surgical Group, Dallas, TX; McLaren Regional Medical Center, Flint, MI; Allegheny General Hospital, Allegheny Cancer Center, Pittsburgh, PA
| |
Collapse
|
22
|
Chagpar A, Blumencranz P, Whitworth P, Deck K, Rosenberg A, Simmons R, Reintgen D, Beitsch P, Julian T, Saha S, Giuliano A, McMasters K, Mamounas E. QS109. Validation of a Clinical Prediction Rule for Patients' Likelihood of Requiring Post-Mastectomy Radiation Therapy. J Surg Res 2009. [DOI: 10.1016/j.jss.2008.11.405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
23
|
Julian TB, Blumencranz P, Deck K, Whitworth P, Berry DA, Berry SM, Rosenberg A, Chagpar AB, Reintgen D, Beitsch P, Simmons R, Saha S, Mamounas EP, Giuliano A. Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer. J Clin Oncol 2008; 26:3338-45. [PMID: 18612150 DOI: 10.1200/jco.2007.14.0665] [Citation(s) in RCA: 71] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE An accurate, intraoperative sentinel lymph node (SLN) test could decrease delayed axillary dissections. Molecular tests may be more sensitive than current intraoperative tests but historically have not been rapid enough and have not been properly validated. We present the results from a large, prospective evaluation of the first rapid molecular SLN test, the Breast Lymph Node (BLN) Assay. METHODS A beta trial (n = 304) to determine the threshold levels of mammaglobin and cytokeratin 19 correlating with metastasis greater than 0.2 mm and a validation trial (n = 416) to validate the threshold cutoffs were conducted. Alternating portions from each SLN were processed for histology and the BLN Assay. RESULTS BLN Assay performance against extensive permanent-section histology verified by central pathology review was similar to that expected of standard permanent-section histology: sensitivity, 87.6%; specificity, 94.2%; positive predictive value, 86.2%; and negative predictive value (NPV), 94.9%. In 319 patients with both frozen-section hematoxylin and eosin results and BLN Assay results, the BLN Assay had higher sensitivity (95.6%) and NPV (98.2%) than frozen section (sensitivity, 85.6%; NPV, 94.5%). The assay can be performed in approximately 36 to 46 minutes for one to three nodes. CONCLUSION The BLN Assay allows a rapid evaluation of 50% of each SLN. Comparison with permanent-section histology on adjacent node pieces evaluated by expert pathologists indicated that the BLN Assay was more sensitive than current intraoperative techniques while maintaining high specificity. These data indicate that the assay may be clinically useful for intraoperative or postoperative axillary lymph node dissection decisions.
Collapse
Affiliation(s)
- Thomas B Julian
- Allegheny Breast Care Center, Allegheny General Hospital, 320 E North Ave, Pittsburgh, PA 15212, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Blumencranz P, Whitworth PW, Deck K, Rosenberg A, Reintgen D, Beitsch P, Chagpar A, Julian T, Saha S, Mamounas E, Giuliano A, Simmons R. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors. Am J Surg 2007; 194:426-32. [PMID: 17826050 DOI: 10.1016/j.amjsurg.2007.07.008] [Citation(s) in RCA: 84] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2007] [Revised: 07/03/2007] [Accepted: 07/03/2007] [Indexed: 11/28/2022]
Abstract
BACKGROUND When sentinel node dissection reveals breast cancer metastasis, completion axillary lymph node dissection is ideally performed during the same operation. Intraoperative histologic techniques have low and variable sensitivity. A new intraoperative molecular assay (GeneSearch BLN Assay; Veridex, LLC, Warren, NJ) was evaluated to determine its efficiency in identifying significant sentinel lymph node metastases (>.2 mm). METHODS Positive or negative BLN Assay results generated from fresh 2-mm node slabs were compared with results from conventional histologic evaluation of adjacent fixed tissue slabs. RESULTS In a prospective study of 416 patients at 11 clinical sites, the assay detected 98% of metastases >2 mm and 88% of metastasis greater >.2 mm, results superior to frozen section. Micrometastases were less frequently detected (57%) and assay positive results in nodes found negative by histology were rare (4%). CONCLUSIONS The BLN Assay is properly calibrated for use as a stand alone intraoperative molecular test.
Collapse
Affiliation(s)
- Peter Blumencranz
- Breast Health Services, Morton Plant Mease Health Care, 303 Pinellas St, Ste. 310, Clearwater, FL 33756, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Blumencranz P, Deck KB, Whitworth PW, McCue P, Reintgen DS, Beitsch P, Chagpar AS, Julian TB, Mamounas M, Simmons R. An investigational rapid RT-PCR assay for the detection of metastasis in sentinel lymph nodes shows improved performance over frozen section H&E: Analysis by primary tumor characteristics. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.10561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10561 Background: In order for a RT-PCR test to accurately diagnose the metastatic status of sentinel lymph nodes the test must perform well across all primary tumor types. Methods: A prospective study was conducted at 11 clinical sites to evaluate a real- time RT-PCR assay (investigational GeneSearch™ Breast Lymph Node Assay, Veridex, LLC, Warren, NJ, USA) for the detection of sentinel lymph node metastasis in patients with invasive breast cancer. Detection limits were pre-set to detect only metastases that are clinically relevant (> 0.2 mm). Tumor information such as tumor stage, size, type and other molecular characteristics were collected. RT-PCR assay was then compared against permanent section H&E and IHC for final performance calculations. A total of 416 patients’ results were analyzed for overall assay performance: sensitivity 87.6% and specificity 94.2%. The assay was then evaluated within each primary tumor characteristics category. Results: Overall RT-PCR sensitivity is an improvement (p= 0.039) over that of current intra-operative methods (frozen section H&E), while specificity is similar (p=0.054). For the various tumor sub-types, in a matched dataset, the RT-PCR assay has up to 35.7% (Invasive Lobular) higher sensitivity compared to frozen section H&E. Conclusions: The data suggest that the RT-PCR assay performs well and has higher sensitivity than frozen section H&E regardless of primary tumor characteristics and, therefore, can be used to detect metastasis for all types of invasive breast cancer. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. Blumencranz
- Morton Plant Mease Healthcare, Clearwater, FL; Saddleback Memorial Hospital, Laguna Hills, CA; Nashville Breast Center, Nashville, TN; Jefferson Medical College, Philadelphia, PA; Lakeland Regional Medical Center, Lakeland, FL; James Brown Cancer Center, Louisville, KY; Dallas Surgical Group, Dallas, TX; Allegheny General Hospital, Pittsburgh, PA; Aultman Hospital, Canton, OH; Weill-Cornell Breast Center, New York, NY
| | - K. B. Deck
- Morton Plant Mease Healthcare, Clearwater, FL; Saddleback Memorial Hospital, Laguna Hills, CA; Nashville Breast Center, Nashville, TN; Jefferson Medical College, Philadelphia, PA; Lakeland Regional Medical Center, Lakeland, FL; James Brown Cancer Center, Louisville, KY; Dallas Surgical Group, Dallas, TX; Allegheny General Hospital, Pittsburgh, PA; Aultman Hospital, Canton, OH; Weill-Cornell Breast Center, New York, NY
| | - P. W. Whitworth
- Morton Plant Mease Healthcare, Clearwater, FL; Saddleback Memorial Hospital, Laguna Hills, CA; Nashville Breast Center, Nashville, TN; Jefferson Medical College, Philadelphia, PA; Lakeland Regional Medical Center, Lakeland, FL; James Brown Cancer Center, Louisville, KY; Dallas Surgical Group, Dallas, TX; Allegheny General Hospital, Pittsburgh, PA; Aultman Hospital, Canton, OH; Weill-Cornell Breast Center, New York, NY
| | - P. McCue
- Morton Plant Mease Healthcare, Clearwater, FL; Saddleback Memorial Hospital, Laguna Hills, CA; Nashville Breast Center, Nashville, TN; Jefferson Medical College, Philadelphia, PA; Lakeland Regional Medical Center, Lakeland, FL; James Brown Cancer Center, Louisville, KY; Dallas Surgical Group, Dallas, TX; Allegheny General Hospital, Pittsburgh, PA; Aultman Hospital, Canton, OH; Weill-Cornell Breast Center, New York, NY
| | - D. S. Reintgen
- Morton Plant Mease Healthcare, Clearwater, FL; Saddleback Memorial Hospital, Laguna Hills, CA; Nashville Breast Center, Nashville, TN; Jefferson Medical College, Philadelphia, PA; Lakeland Regional Medical Center, Lakeland, FL; James Brown Cancer Center, Louisville, KY; Dallas Surgical Group, Dallas, TX; Allegheny General Hospital, Pittsburgh, PA; Aultman Hospital, Canton, OH; Weill-Cornell Breast Center, New York, NY
| | - P. Beitsch
- Morton Plant Mease Healthcare, Clearwater, FL; Saddleback Memorial Hospital, Laguna Hills, CA; Nashville Breast Center, Nashville, TN; Jefferson Medical College, Philadelphia, PA; Lakeland Regional Medical Center, Lakeland, FL; James Brown Cancer Center, Louisville, KY; Dallas Surgical Group, Dallas, TX; Allegheny General Hospital, Pittsburgh, PA; Aultman Hospital, Canton, OH; Weill-Cornell Breast Center, New York, NY
| | - A. S. Chagpar
- Morton Plant Mease Healthcare, Clearwater, FL; Saddleback Memorial Hospital, Laguna Hills, CA; Nashville Breast Center, Nashville, TN; Jefferson Medical College, Philadelphia, PA; Lakeland Regional Medical Center, Lakeland, FL; James Brown Cancer Center, Louisville, KY; Dallas Surgical Group, Dallas, TX; Allegheny General Hospital, Pittsburgh, PA; Aultman Hospital, Canton, OH; Weill-Cornell Breast Center, New York, NY
| | - T. B. Julian
- Morton Plant Mease Healthcare, Clearwater, FL; Saddleback Memorial Hospital, Laguna Hills, CA; Nashville Breast Center, Nashville, TN; Jefferson Medical College, Philadelphia, PA; Lakeland Regional Medical Center, Lakeland, FL; James Brown Cancer Center, Louisville, KY; Dallas Surgical Group, Dallas, TX; Allegheny General Hospital, Pittsburgh, PA; Aultman Hospital, Canton, OH; Weill-Cornell Breast Center, New York, NY
| | - M. Mamounas
- Morton Plant Mease Healthcare, Clearwater, FL; Saddleback Memorial Hospital, Laguna Hills, CA; Nashville Breast Center, Nashville, TN; Jefferson Medical College, Philadelphia, PA; Lakeland Regional Medical Center, Lakeland, FL; James Brown Cancer Center, Louisville, KY; Dallas Surgical Group, Dallas, TX; Allegheny General Hospital, Pittsburgh, PA; Aultman Hospital, Canton, OH; Weill-Cornell Breast Center, New York, NY
| | - R. Simmons
- Morton Plant Mease Healthcare, Clearwater, FL; Saddleback Memorial Hospital, Laguna Hills, CA; Nashville Breast Center, Nashville, TN; Jefferson Medical College, Philadelphia, PA; Lakeland Regional Medical Center, Lakeland, FL; James Brown Cancer Center, Louisville, KY; Dallas Surgical Group, Dallas, TX; Allegheny General Hospital, Pittsburgh, PA; Aultman Hospital, Canton, OH; Weill-Cornell Breast Center, New York, NY
| |
Collapse
|
26
|
Leitch AM, McCall L, Beitsch P, Whitworth P, Reintgen D, Blumencranz P, Saha S, Bauer T, Hunt KK, Giuliano A. Factors influencing accrual to ACOSOG Z0011, a randomized phase III trial of axillary dissection vs. observation for sentinel node positive breast cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.601] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
601 Background: The American College of Surgeons Oncology Group opened a phase III randomized trial to assess the value of axillary node dissection (ALND) after positive sentinel node biopsy (SNB). After 5.5 years, the trial closed due to poor accrual with only 891 patients of the planned 1900 accrued. The purpose of the current analysis is to assess factors impacting accrual to Z0011. Methods: Women having SNB for T1 or T2 breast cancer were eligible for participation in the Z0010 trial to assess the significance of micrometastases identified by immunohistochemistry. If the SN was positive for metastasis by H&E, the patient was eligible for randomization on Z0011 trial. Intraoperative (IOR) and postoperative randomization were allowed. Patients having SNB outside of the Z0010 trial were eligible. Results: 1003 patients from the Z0010 trial were eligible for randomization on Z0011. Of these, only 37% were entered in Z0011. Z0010 participants accounted for 42% of patients in Z0011. 16% of patients not randomized refused ALND. 69% of those not randomized had ALND. 67% of these had no additional positive nodes. Only 14% had ≥ 4 positive nodes. Enrollment of eligible Z0010 patients varied by type of institution: 25% at academic sites, 42% at teaching affiliated and 53% at community (p < 0.0001). By geographic region, sites in the South entered 42% of eligible patients compared with 24–36% in other geographic regions (p=0.0027). Only 32% of patients were consented for IOR based on frozen section of the SN. Sites in the South and West were less likely to use IOR (25% and 28%) compared to Northeast and Midwest (45% and 46%) (p < 0.0001). 110 sites participated in Z0011, yet 48% of patients were enrolled by 10% of sites. Conclusions: Failure of this important trial to accrue as planned is likely related to the clinical bias of physicians and patients to standard ALND. Yet, 2/3 of patients had no additional positive nodes and extensive nodal disease was infrequent. While it was thought that IOR might improve accrual to Z0011, the most successful sites were less likely to use this approach. Community surgeons were most successful in randomizing patients. [Table: see text]
Collapse
Affiliation(s)
- A. M. Leitch
- UT Southwestern Medical Center, Dallas, TX; Duke University, Durham, NC; Dallas Surgical Group, Dallas, TX; Nashville Breast Center, Nashville, TN; Lakeland Regional Cancer Center, Lakeland, FL; Morton Plant Mease Health Care, Clearwater, FL; McLaren Regional Medical Center, Flint, MI; Apple Hill Surgical Associates, York, PA; M. D. Anderson Cancer Center, Houston, TX; John Wayne Cancer Institute, Santa Monica, CA
| | - L. McCall
- UT Southwestern Medical Center, Dallas, TX; Duke University, Durham, NC; Dallas Surgical Group, Dallas, TX; Nashville Breast Center, Nashville, TN; Lakeland Regional Cancer Center, Lakeland, FL; Morton Plant Mease Health Care, Clearwater, FL; McLaren Regional Medical Center, Flint, MI; Apple Hill Surgical Associates, York, PA; M. D. Anderson Cancer Center, Houston, TX; John Wayne Cancer Institute, Santa Monica, CA
| | - P. Beitsch
- UT Southwestern Medical Center, Dallas, TX; Duke University, Durham, NC; Dallas Surgical Group, Dallas, TX; Nashville Breast Center, Nashville, TN; Lakeland Regional Cancer Center, Lakeland, FL; Morton Plant Mease Health Care, Clearwater, FL; McLaren Regional Medical Center, Flint, MI; Apple Hill Surgical Associates, York, PA; M. D. Anderson Cancer Center, Houston, TX; John Wayne Cancer Institute, Santa Monica, CA
| | - P. Whitworth
- UT Southwestern Medical Center, Dallas, TX; Duke University, Durham, NC; Dallas Surgical Group, Dallas, TX; Nashville Breast Center, Nashville, TN; Lakeland Regional Cancer Center, Lakeland, FL; Morton Plant Mease Health Care, Clearwater, FL; McLaren Regional Medical Center, Flint, MI; Apple Hill Surgical Associates, York, PA; M. D. Anderson Cancer Center, Houston, TX; John Wayne Cancer Institute, Santa Monica, CA
| | - D. Reintgen
- UT Southwestern Medical Center, Dallas, TX; Duke University, Durham, NC; Dallas Surgical Group, Dallas, TX; Nashville Breast Center, Nashville, TN; Lakeland Regional Cancer Center, Lakeland, FL; Morton Plant Mease Health Care, Clearwater, FL; McLaren Regional Medical Center, Flint, MI; Apple Hill Surgical Associates, York, PA; M. D. Anderson Cancer Center, Houston, TX; John Wayne Cancer Institute, Santa Monica, CA
| | - P. Blumencranz
- UT Southwestern Medical Center, Dallas, TX; Duke University, Durham, NC; Dallas Surgical Group, Dallas, TX; Nashville Breast Center, Nashville, TN; Lakeland Regional Cancer Center, Lakeland, FL; Morton Plant Mease Health Care, Clearwater, FL; McLaren Regional Medical Center, Flint, MI; Apple Hill Surgical Associates, York, PA; M. D. Anderson Cancer Center, Houston, TX; John Wayne Cancer Institute, Santa Monica, CA
| | - S. Saha
- UT Southwestern Medical Center, Dallas, TX; Duke University, Durham, NC; Dallas Surgical Group, Dallas, TX; Nashville Breast Center, Nashville, TN; Lakeland Regional Cancer Center, Lakeland, FL; Morton Plant Mease Health Care, Clearwater, FL; McLaren Regional Medical Center, Flint, MI; Apple Hill Surgical Associates, York, PA; M. D. Anderson Cancer Center, Houston, TX; John Wayne Cancer Institute, Santa Monica, CA
| | - T. Bauer
- UT Southwestern Medical Center, Dallas, TX; Duke University, Durham, NC; Dallas Surgical Group, Dallas, TX; Nashville Breast Center, Nashville, TN; Lakeland Regional Cancer Center, Lakeland, FL; Morton Plant Mease Health Care, Clearwater, FL; McLaren Regional Medical Center, Flint, MI; Apple Hill Surgical Associates, York, PA; M. D. Anderson Cancer Center, Houston, TX; John Wayne Cancer Institute, Santa Monica, CA
| | - K. K. Hunt
- UT Southwestern Medical Center, Dallas, TX; Duke University, Durham, NC; Dallas Surgical Group, Dallas, TX; Nashville Breast Center, Nashville, TN; Lakeland Regional Cancer Center, Lakeland, FL; Morton Plant Mease Health Care, Clearwater, FL; McLaren Regional Medical Center, Flint, MI; Apple Hill Surgical Associates, York, PA; M. D. Anderson Cancer Center, Houston, TX; John Wayne Cancer Institute, Santa Monica, CA
| | - A. Giuliano
- UT Southwestern Medical Center, Dallas, TX; Duke University, Durham, NC; Dallas Surgical Group, Dallas, TX; Nashville Breast Center, Nashville, TN; Lakeland Regional Cancer Center, Lakeland, FL; Morton Plant Mease Health Care, Clearwater, FL; McLaren Regional Medical Center, Flint, MI; Apple Hill Surgical Associates, York, PA; M. D. Anderson Cancer Center, Houston, TX; John Wayne Cancer Institute, Santa Monica, CA
| |
Collapse
|
27
|
Shivers S, Cox C, Leight G, Beauchamp D, Blumencranz P, Ross M, Reintgen D. Final results of the Department of Defense multicenter breast lymphatic mapping trial. Ann Surg Oncol 2002; 9:248-55. [PMID: 11923131 DOI: 10.1007/bf02573062] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Lymphatic mapping and sentinel lymph node (SLN) biopsy have the potential to become the standard of care for nodal staging in breast cancer patients, but their widespread utility outside of university-based centers has not been determined. This study describes the final results from a national multi-institutional trial designed to determine the role of preoperative lymphoscintigraphy in breast lymphatic mapping, the rate of success for finding an SLN, and the rate of skip metastasis for patients with invasive breast cancer across all practice scenarios. METHODS Lymphatic mapping techniques involving the combined use of blue dye and radiocolloid were taught to participating surgeons through a formal 2-day training course at the Moffitt Cancer Center. In protocol 1, surgeons performed their first 20 to 25 cases of breast mapping with SLN biopsy followed by complete axillary lymph node dissection. In protocol 2, after the learning phase, surgeons did not perform axillary lymph node dissection unless a SLN was positive for metastatic disease. RESULTS Forty-two institutions, including 12 university-based research centers, participated in the trial. From July 1, 1997, through January 31, 1999, a total of 965 patients were accrued. Lymphoscintigraphy identified drainage to an axillary SLN 64% of the time, but by using sensitive handheld gamma probes at the time of the operation, an axillary SLN could be identified 86% of the time. The rate of success for finding an axillary SLN was 92.8% for cases performed at the Moffitt Cancer Center. For other university centers, the rate of success of identifying an axillary SLN was 91.4%, and for other community/regional hospitals in the study, it was 85.2%. For cases in which protocol 1 was followed, the rate of false-negative SLN biopsy was 4%. There was no axillary nodal recurrence after a negative SLN in protocol 2 when a negative SLN biopsy was followed by observation. The median follow-up for the patients on protocol 2 was 16 months. CONCLUSIONS These data show a high rate of success for finding an axillary SLN and a low rate of skip metastasis in a national multicenter study of lymphatic mapping for breast cancer. This study suggests that SLN biopsy for breast cancer can be performed successfully in community/regional hospitals, as well as in major university-based centers.
Collapse
Affiliation(s)
- Steve Shivers
- Department of Surgery, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida, USA
| | | | | | | | | | | | | |
Collapse
|
28
|
Dupont EL, Kamath VJ, Ramnath EM, Shivers SC, Cox C, Berman C, Leight GS, Ross MI, Blumencranz P, Reintgen DS. The Role of Lymphoscintigraphy in the Management of the Patient With Breast Cancer. Ann Surg Oncol 2001; 8:354-60. [PMID: 11352310 DOI: 10.1007/s10434-001-0354-4] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
INTRODUCTION Regional nodal status is the most powerful predictor of recurrence and survival in women with breast cancer. Lymphatic mapping and sentinel lymph node (SLN) biopsy have been found to accurately predict the regional nodal status. Preoperative lymphoscintigraphy has been used in melanoma patients to identify the basins at risk for metastases when primary sites are located in watershed areas of the body. This study was performed to define the role of lymphoscintigraphy for axillary nodal staging in women with breast cancer. Specifically, can preoperative lymphoscintigraphy define a population of women with breast cancer who have multidirectional drainage or who do not drain to the axilla and need no axillary dissection? METHODS 516 patients with invasive breast cancer were accrued in a national breast lymphatic mapping trial sponsored by the U.S. Department of Defense. Preoperative lymphoscintigraphy images were produced using filtered technetium-99 sulfur colloid. Lymphatic drainage to axillary and internal mammary sites was noted. RESULTS Drainage to an axillary SLN was found in 335 (65%) patients, and internal mammary or extra-axillary drainage was noted in 52 (10%) patients. By using sensitive hand-held probes and vital blue dye intraoperatively, the overall success rate of finding an axillary SLN was 85%. Of the 335 patients who had an axillary SLN identified with imaging, all had successful SLN biopsy procedures. Although no SLNs could be imaged in 181 patients, 153 (85%) of these patients had an axillary SLN identified with intraoperative mapping. For 28 patients in which lymphoscintigraphy was negative and intraoperative mapping was unsuccessful, complete axillary node dissection was performed, and 13 (46%) of these patients were found to have metastatic disease in the basin. CONCLUSIONS Preoperative lymphoscintigraphy can identify those women with primary breast cancers who have extra-axillary regional basin drainage such as internal mammary. The ability to image an axillary SLN was associated with a high success rate of being able to find the node intraoperatively with a combination mapping technique. In a high percentage of patients with negative lymphoscintigraphy, the SLN was identified with more sensitive hand-held probes. Therefore, patients who have a negative preoperative lymphoscintigraphy and intraoperatively are found to have no "hot" spot in the axilla with the hand-held probe still need an axillary node dissection, because 46% of these patients contain metastatic disease in the axilla.
Collapse
Affiliation(s)
- E L Dupont
- H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa 33612-9497, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Turnbull A, Blumencranz P, Fortner J. Scapulectomy for soft tissue sarcoma. Can J Surg 1981; 24:37-8. [PMID: 7459733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Between 1961 and 1978, 19 patients with primary soft tissue sarcomas were treated by resection of part or all of the scapula and musculoaponeurotic attachments. Recurrence-free survival was from 2 to 18 years (mean 10.7 years) in all six patients with a histologically low-grade fibrosarcoma and from 2.5 to 9 years (mean 4.9 years) in three of six patients with high-grade tumours. In all 12 patients the margin of resection was satisfactory. In contrast, only two of seven patients with high-grade sarcomas and gross or microscopically involved resection margins were alive 1 year after operation. Long-term salvage or cure of soft tissue sarcomas at this or other sites depends upon the histologic grade of the tumour and the feasibility of an adequately wide monobloc excision. Adjunctive measures to diminish the likelihood of local recurrence and to avoid amputation in marginal situations include intraoperative brachytherapy (with iodine-125 or iridium-192) and supplemental external radiotherapy. Recent experience with intensive multiple-agent chemotherapy indicates an appreciable reduction in the occurrence of systemic metastases from tumours with this potential.
Collapse
|